Document:

<PAGE>

CONFIDENTIAL

                                                                   Exhibit 10.34

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                             Co-Promotion Agreement

                                     Between

                            Ross Products Division of
                            Abbott Laboratories Inc.

                                       and

                                  Sepracor Inc.

                          Dated As Of November 19, 1999
<PAGE>

CONFIDENTIAL

                                Table of Contents

Article 1.  Definitions.......................................................1

Article 2.  APPOINTMENT TO CO-PROMOTE.........................................7
      2.1   Appointment.......................................................7
      2.2   Marketing Committee...............................................8
      2.3   Perform the tasks or functions specified in Section 1.31,
            Section 1.32, Section 3.6.2, and Section 4.15. 2..................9

Article 3.  ABBOTT PROMOTIONAL EFFORTS........................................9
      3.1   Abbott Promotional Efforts........................................9
      3.2   Product Manager and Sales Force..................................11
      3.3   Abbott Representative Training...................................11
      3.4   Abbott Representatives' Incentive Compensation...................12
      3.5   Requests for Medical Information by Third Parties................12
      3.6   Abbott Reports...................................................12
      3.7   Other Abbott Costs and Expenses..................................13

Article 4.  SEPRACOR RESPONSIBILITIES AND PROMOTIONAL EFFORTS................13
      4.1   Pediatric Expanded Approval......................................13
      4.2   Maintenance of Product NDA.......................................13
      4.3   Product Formulations.............................................13
      4.4   Regulatory Responsibilities......................................13
      4.5   Patent and Proprietary Protection................................14
      4.6   Consultation with Abbott.........................................14
      4.7   Product Manufacture..............................................14
      4.8   Complaints, Product Defects and Returns..........................15
      4.9   Product Supply...................................................15
      4.10  Sepracor Promotional Efforts.....................................15
      4.11  Product Manager..................................................16
      4.12  Sepracor Representative Training.................................16
      4.13  Sepracor Representatives' Incentive Compensation.................17
      4.14  Requests for Medical Information by Third Parties................17
      4.15  Sepracor Reports.................................................17
      4.16  Other Sepracor Costs and Expenses................................17

Article 5.  LABELING, SAMPLING AND PROMOTIONAL MATERIALS.....................18
      5.1   Product Labeling.................................................18
      5.2   Sampling.........................................................18
      5.3   Development of Sepracor Promotional Materials....................18
      5.4   Distribution of Sepracor Promotional Materials...................18
      5.5   Identification of Abbott on Sepracor Promotional Materials.......19
      5.6   Abbott Product Materials.........................................20
      5.7   Identification of Sepracor on Abbott Product Materials...........20

                                        i
<PAGE>

CONFIDENTIAL

Article 6.  PRICING, QUOTATIONS, ORDERS, BILLING, COLLECTION AND
            SALES TRACKING...................................................21
      6.1   Pricing..........................................................21
      6.2   Pricing and Rebate Contracts.....................................21
      6.3   Quotations and Orders; Billing and Collection....................21
      6.4   Electronic Database..............................................21

Article 7.  COMPENSATION TO ABBOTT...........................................22
      7.1   Commission.......................................................22
      7.2   Commission Payment...............................................22
      7.3   Audit............................................................22

Article 8.  MEDICAL INQUIRIES; NOTIFICATION OF ADVERSE
            DRUG EXPERIENCE..................................................23
      8.1   Communication....................................................23
      8.2   Notification.....................................................23
      8.3   Product Report...................................................24
      8.4   Product Recall...................................................24

Article 9.  OTHER PRODUCTS...................................................24
      9.1   Product Rights Ex-U.S............................................24
      9.2   Product Rights to Geriatric Market...............................24
      9.3   Rights of Negotiation for Other Products.........................25

Article 10. REPRESENTATIONS AND WARRANTIES; COVENANTS........................25
      10.1  Mutual Representations and Warranties............................25
      10.2  Abbott Covenants.................................................25
      10.3  Other Abbott Representations and Warranties......................26
      10.4  Other Sepracor Representations and Warranties....................27
      10.5  Sepracor Covenants...............................................28

Article 11. INDEPENDENT CONTRACTOR RELATIONSHIP..............................29

Article 12. TERM AND TERMINATION.............................................29
      12.1  Initial Term.....................................................29
      12.2  Early Termination by Abbott......................................29
      12.3  Early Termination by Either Party................................30
      12.4  Grace Period.....................................................31

Article 13. CONSEQUENCES OF TERMINATION......................................31
      13.1  Confidential Information.........................................31
      13.2  Accrued Obligations..............................................31
      13.3  Return of Promotional Materials..................................31
      13.4  Commission.......................................................32
      13.5  Residual Commission..............................................32
      13.6  Remedies.........................................................32

                                       ii
<PAGE>

CONFIDENTIAL

      13.7  Survival.........................................................32

Article 14. INDEMNIFICATION..................................................33
      14.1  Sepracor Indemnification.........................................33
      14.2  Abbott Indemnification...........................................34
      14.3  Sepracor Indemnification Under Sampling Act......................35
      14.4  Abbott Indemnification Under Sampling Act........................36
      14.5  Control of Defense...............................................37
      14.6  Settlement of Claims.............................................38

Article 15. CONFIDENTIALITY..................................................38
      15.1  Definition.......................................................38
      15.2  Exceptions to the Definition of Confidential Information.........38
      15.3  Confidentiality Obligations......................................39
      15.4  Previous Agreement...............................................39

Article 16. PUBLIC ANNOUNCEMENTS.............................................39
      16.1  Joint Announcement...............................................39
      16.2  Non-Publicity....................................................40

Article 17. TRADEMARKS.......................................................40
      17.1  Promotion........................................................40
      17.2  Compliance with Laws.............................................40
      17.3  No Assertion of Right............................................40

Article 18. FORCE MAJEURE....................................................41

Article 19. ALTERNATIVE DISPUTE RESOLUTION...................................41

Article 20. GENERAL..........................................................41
      20.1  Property Interest................................................41
      20.2  Assignment.......................................................41
      20.3  Headings.........................................................42
      20.4  Notices..........................................................42
      20.5  Waiver...........................................................43
      20.6  Severability.....................................................43
      20.7  Governing Law....................................................43
      20.8  Counterparts.....................................................43
      20.9  Entire Agreement.................................................43

SCHEDULE 1.32.    Sample Pediatric Sales Calculation

SCHEDULE 10.4.6.  Other Agreements Regarding Product

SCHEDULE 10.4.7.  Notices From The FDA

SCHEDULE 19       Alternative Dispute Resolution

                                       iii
<PAGE>

CONFIDENTIAL

                             CO-PROMOTION AGREEMENT

      THIS CO-PROMOTION AGREEMENT (the "Agreement") is entered into as of
November 19, 1999 (the "Effective Date"), by and between Sepracor Inc., having
its principal offices at 111 Locke Drive, Suite 2, Marlborough, Massachusetts
01752 ("Sepracor"), and Abbott Laboratories Inc., through its Ross Products
Division, having its principal offices at 625 Cleveland Avenue, Columbus, Ohio
43215 ("Abbott").

                                   WITNESSETH:

      WHEREAS, Sepracor has received FDA approval for an inhalation solution of
levalbuterol hydrochloride which is currently marketed in the United States of
America under Sepracor's trademark, Xopenex(TM);

      WHEREAS, Abbott has a well-established and highly trained pediatric sales
force for promoting pharmaceutical products; and

      WHEREAS, Sepracor and Abbott wish to enter into this Agreement for Abbott
to co-promote the product(s) described herein in the Territory;

      NOW, THEREFORE, in consideration of the representations, warranties,
covenants and agreements set forth herein, the parties agree as follows:

Article 1.  DEFINITIONS.

      For the purposes of this Agreement, the following initially capitalized
terms in this Agreement, whether used in the singular or plural, shall have the
following meanings, unless the context clearly requires otherwise.

      1.1   "Abbott" means the Ross Products Division of Abbott Laboratories
            Inc., a Delaware corporation.

      1.2   "Abbott Diversion Violation" means a violation of the Sampling Act
            that is caused by Abbott, its officers, directors, or other
            employees or representatives of Abbott in the performance of
            Abbott's obligations under this Agreement, which occurs and is
            deemed a conviction against Sepracor pursuant to 21 U.S.C.
            ss.333(b)(2).

      1.3   "Abbott Marks" means the corporate names "Abbott Laboratories" and
            "Abbott Laboratories Inc.," the division names "Ross Products
            Division" and "Ross Pediatrics," and Abbott's logo "a" and the
            "Ross" logo.

      1.4   "Abbott Product Materials" means all forms and formats of
            information produced by or at the request of Abbott regarding or
            describing, in whole or in part, the Product, developed for use in
            promoting the Product.

      1.5   "Abbott Promotional Efforts" means Abbott's activities to promote
            and sell the Product as defined in Article 3 of this Agreement.

                                        1
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

      1.6   "Abbott Representative" means an individual who is an employee
            person of Abbott, who has been trained by Abbott to make sales
            presentations for Abbott's pediatric pharmaceutical and nutritional
            products, and who has been trained pursuant to this Agreement to
            make effective sales presentations for the Product.

      1.7   "Abbott Targeted Hospitals" means all hospitals classified as Outlet
            Subcategory Codes [**] using Drug Distribution Data.

      1.8   "ADR" means the alternative dispute resolution process set forth in
            Article19.

      1.9   "Affiliate" means, with respect to each Party, any legal entity
            which, during the Term, controls, is controlled by, or is under
            common control with such Party. For purposes of this definition, an
            entity shall be deemed to control another entity if it owns or
            controls, directly or indirectly, at least fifty percent (50%) of
            the voting interest of all equity interests of the other entity (or
            other comparable ownership interest for an entity other than a
            corporation).

      1.10  "Agreement" means this Co-Promotion Agreement executed by both
            Parties, as may be amended from time to time in accordance with the
            terms and conditions hereof.

      1.11  "Approved Indication" for the Product means:

            1.11.1  Prevention and/or treatment of bronchospasm in adolescents
                    12 years of age and older with reversible obstructive airway
                    disease; or

            1.11.2  Any other indications approved by the FDA during the Term.

      1.12  "Average Net Selling Price/Dose Vial" means the Net Sales of unit
            dose vials of Product during a Sales Quarter, divided by the number
            of unit dose vials of Product actually sold during such Sales
            Quarter (excluding actual rejections and returns in such Sales
            Quarter).

      1.13  "Average Net Selling Price/Dose Bottle" means the Net Sales of
            multidose bottles of Product during a Sales Quarter, divided by the
            number of multidose bottles of Product actually sold during such
            Sales Quarter (excluding actual rejections and returns in such Sales
            Quarter).

      1.14  "cGMP" means current Good Manufacturing Practices, as defined by the
            FDA pursuant to applicable statutes and the regulations adopted from
            time to time under authority of the Federal Food, Drug and Cosmetics
            Act.

      1.15  "Commission" means the dollar amount of compensation paid to Abbott
            for the Abbott Promotional Efforts and other obligations of Abbott
            hereunder, based on Pediatric Sales for any given Sales Year during
            the Term, as computed and paid on a quarterly basis.

                                       2
<PAGE>

CONFIDENTIAL

      1.16  "Commission Payments" means the quarterly payments made by Sepracor
            to Abbott calculated in accordance with the provisions set forth in
            Section 7.1.

      1.17  "Confidential Information" shall have the meaning set forth in
            Section 15.1.

      1.18  "Effective Date" means the date first above written in the Preamble
            to this Agreement.

      1.19  "Extension Term" means the twelve-month period of time following the
            end of the Initial Term , which is an extension of the Term in
            accordance with the provisions of Section 12.1.1.

      1.20  "FDA" means the United States Food and Drug Administration or any
            successor entity thereto.

      1.21  "Geriatric Market" means the population segment of people age 65
            years and older.

      1.22  "Initial Term" means the period of time commencing on the Effective
            Date and ending on the sixth anniversary of January 1, 2000.

      1.23  "Initial Training" means the training of the Abbott Representatives
            by Sepracor in accordance with the provisions set forth in Section
            3.3.1.

      1.24  "Line Extension" shall mean any (a) new formulation or dosage
            strength of levalbuterol hydrochloride inhalation solution for use
            in a standard nebulization unit, (b) new indication for levalbuterol
            hydrochloride inhalation solution, or (c) new packaging or labeling
            configurations for levalbuterol hydrochloride inhalation solution.

      1.25  "Marketing Committee" means a committee comprised of two (2)
            designees of each Party, which shall meet as set forth in Section
            2.2 regarding the matters set forth therein.

      1.26  "Medical Affairs Liaison" of each Party shall mean a person
            appointed by each Party, with notice to the other Party of the name,
            address, telephone number and facsimile number for such person, to
            facilitate the communications described in Article 8.

      1.27  "NDA" means a new drug application (or a supplemental new drug
            application) submitted to the FDA for approval of the Product for
            commercial sale for indicated uses pursuant to the Federal Food,
            Drug, and Cosmetic Act.

      1.28  "Net Sales" means the gross amount invoiced by Sepracor or its
            Affiliates on sales of a Product in the Territory, less the
            following as they specifically relate to the Product:

                                       3
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

            1.28.1  [**] and [**];

            1.28.2  [**] or [**] for [**], and [**]

            1.28.3  [**] with respect to sales of Product (including [**] or
                    otherwise [**] the sale of Product, including [**] when
                    included in the [**] with respect to [**] included in the
                    [**]

            1.28.4  [**] costs incurred in [**] included in the [**]

            1.28.5  [**] and [**] or to [**] and [**] and [**] or to [**]
                    including, [**]

            1.28.6  [**] provided that such [**] and are [**]

            1.28.7  in the event [**] the Product, then, if possible, the [**]
                    shall be [**] to which [**], including the Product. In the
                    event [**] including the Product, [**] shall be [**]
                    including the Product.

                                       4
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

            In addition, the following shall apply for the purposes of
            calculating Net Sales: (a) if [**] to a [**] to the [**] of Product
            [**] which is the [**] and the [**] which is the [**] for each and
            every [**]; (b) if [**] to a [**] by or for such [**] for such
            Product shall be [**] or the [**]; and (c) if Product is [**] any
            other [**] or any [**] of any [**] to such [**] in connection with
            [**] shall be [**] in the [**].

      1.29  "Party" means either Abbott or Sepracor and their respective
            successors and assigns; and "Parties" is both Abbott and Sepracor,
            and their respective successors and assigns.

      1.30  "Pediatric Bronchospasm Expanded Approval" means FDA's approval of
            Sepracor's NDA for the Product for use in children below age 12 and
            at least down to age 4.

      1.31  "Pediatric Market" means pediatricians identified by Medical
            Education number (a list of such pediatricians to be agreed to by
            the Marketing Committee and amended from time to time, as
            appropriate), general and family physician practitioners with high
            birth practices identified by Medical Education number (a list of
            such physicians to be agreed to by the Marketing Committee and
            amended from time to time, as appropriate), and Abbott Targeted
            Hospitals, and clinics, mail-order and staff model health
            maintenance organizations for the purpose of pediatric care;
            provided, however, that all pediatric allergists and pediatric
            pulmonologists are excluded from the Pediatric Market; further,
            provided, however, that Abbott shall have a right of first refusal
            to add pediatric allergists, pediatric pulmonologists, or both, to
            the Pediatric Market in the event that during the Term, Sepracor
            decides that it would like sales personnel other than Sepracor
            Representatives to promote Product to pediatric allergists,
            pediatric pulmonologists, or both, as appropriate, and in such case,
            expansion of the Pediatric Market to include one or both of
            pediatric allergists and pediatric pulmonologists shall be discussed
            by the Marketing Committee.

      1.32  "Pediatric Sales" means sales of Product by Sepracor and its
            Affiliates, as calculated by adding (a) the product determined by
            multiplying the Average Net Selling Price/Dose Vial or Average Net
            Selling Price/Dose Bottle during an applicable period by the number
            of unit dose vials or multidose bottles of Product, as appropriate,
            sold during such period through pediatricians identified by Medical
            Education number (a list of such pediatricians to be agreed to by
            the Marketing Committee and amended from time to time, as
            appropriate), and those general and family physician practitioners
            with high birth practices identified by Medical Education number (a
            list of such physicians to be agreed to by the Marketing Committee
            and amended from time to time, as appropriate), that are dispensed
            by retail drug stores (independent, chains, food and mass
            merchandise stores), clinics, and mail-order and staff model health
            maintenance organizations (determined by multiplying the number of
            prescriptions generated by such pediatricians and general and family
            practitioners and so dispensed

                                       5
<PAGE>

CONFIDENTIAL

            (using Xponent data) by the average number of unit dose vials per
            pediatric script (which is equal to the unit dose ratio (the
            numerator of which is the total milliliter volume of the Product
            dispensed in unit dose vials to fill pediatric prescriptions, and
            the denominator of which is dose size in milliliters) divided by the
            number of unit dose vial prescriptions written by pediatricians) or
            by the average number of multidose bottles per pediatric script
            (which is equal to the multidose ratio (the numerator of which is
            the total milliliter volume of the Product dispensed in multidose
            bottles to fill pediatric prescriptions, and the denominator of
            which is the bottle volume in milliliters) divided by the number of
            multidose bottle prescriptions written by pediatricians) , as
            appropriate, (using the National Prescription Audit), and (b)
            pediatric purchases of Product by hospitals, which shall be
            calculated by multiplying the number of unit dose vials or multidose
            bottles of Product, as appropriate, sold to Abbott Targeted
            Hospitals during an applicable period as reported by Drug
            Distribution Data by the Average Net Selling Price/Dose Vial or
            Average Net Selling Price/Dose Bottle, as appropriate, during such
            period and by the fraction equal to the number of unit dose vials or
            multidose bottles, as appropriate, prescribed by pediatricians in
            the retail segment (as reported by the National Prescription Audit)
            divided by the number of all unit dose vials or multidose bottles,
            as appropriate, prescribed in the retail segment (as reported by the
            National Prescription Audit) during such period. For example
            purposes only, a mock sample calculation of Pediatric Sales is set
            forth in Schedule 1.32 hereto.

      1.33  "Product" means Sepracor's levalbuterol hydrochloride inhalation
            solution, a pharmaceutical product for human use, currently marketed
            under the Trademark. Product shall include any Line Extensions.

      1.34  "Purchasers" means any person or entity purchasing the Product,
            including, but not limited to, wholesalers, distributors and
            Sepracor customers.

      1.35  "Residual Commission" means a Commission paid by Sepracor to Abbott
            following of the Term as set forth in Section 13.5.

      1.36  "Sales Quarter" means each period of three (3) consecutive months
            during the Term; provided, however, that the first Sales Quarter
            shall be the partial Sales Quarter beginning on the date that the
            first Abbott Representatives begin Abbott Promotional Efforts and
            ending on December 31, 1999. The second Sales Quarter shall begin on
            January 1, 2000, with successive Sales Quarters being each
            successive three (3)-month period thereafter.

      1.37  "Sales Year" means a period of twelve (12) consecutive calendar
            months during the Term commencing on January 1, 2000, and each
            anniversary thereof.

      1.38  "Samples" means small quantities of the Product offered for
            evaluation.

                                       6
<PAGE>

CONFIDENTIAL

      1.39  "Sampling Act" means the Prescription Drug Marketing Act of 1988, as
            amended from time to time, and any regulations promulgated
            thereunder.

      1.40  "Sepracor" means Sepracor Inc., a Delaware corporation.

      1.41  "Sepracor Diversion Violation" means a violation of the Sampling Act
            that is caused by Sepracor, its officers, directors, or other
            employees or representatives of Sepracor in the performance of
            Sepracor's obligations under this Agreement, which occurs and is
            deemed a conviction against Abbott pursuant to 21 U.S.C.
            ss.333(b)(2).

      1.42  "Sepracor Marks" means the corporate names "Sepracor Inc.," and
            "Sepracor", and the Trademark and other tradenames and logos of
            Sepracor.

      1.43  "Sepracor Promotional Efforts" means all of Sepracor's activities to
            promote and sell the Product as defined in Section 4.10 of this
            Agreement.

      1.44  "Sepracor Promotional Materials" means original printed matter,
            including printed literature and reprints, or original graphic
            matter relating or referring to the Product, that is provided by
            Sepracor to Abbott for use by the Abbott Representatives in Abbott
            Promotional Efforts.

      1.45  "Sepracor Representative" means an individual who is an employee of
            Sepracor or contract sales person retained or engaged by Sepracor,
            who has been trained by Sepracor to make effective sales
            presentations for the Product.

      1.46  "Term" means the period of time from the Effective Date until the
            expiration or early termination of this Agreement in accordance with
            its terms and conditions. In any event, the Term of this Agreement
            shall not be longer than seven (7) years from the January 1, 2000.

      1.47  "Territory" means the fifty (50) states of the United States of
            America, the District of Columbia, and all United States territories
            and possessions, but excluding Puerto Rico.

      1.48  "Third Party" means a party other than Abbott, Sepracor, or their
            Affiliates.

      1.49  "Trademark" means the statutory United States of America trademark
            Xopenex(TM) for the Product, in the Territory, and any other
            trademark under which the Product is marketed during the Term in the
            Territory.

Article 2. APPOINTMENT TO CO-PROMOTE.

      2.1   Appointment. Sepracor hereby appoints Abbott as the exclusive
            co-promoter of the Product to the Pediatric Market in the Territory
            for the Term, except as set forth in Section 4.10.1 below. Sepracor
            and Abbott hereby agree that Sepracor and Abbott, and their
            respective Representatives, shall be the sole

                                       7
<PAGE>

CONFIDENTIAL

            commercial promoters of the Product to the Pediatric Market in the
            Territory for the Term, subject to the terms and conditions of this
            Agreement. Sepracor shall retain all other rights exclusively to
            promote Product, and all other Sepracor prescription and
            non-prescription pharmaceutical and non-pharmaceutical products.

      2.2   Marketing Committee. Immediately following the Effective Date,
            Abbott and Sepracor shall each appoint two (2) representatives on
            behalf of their respective companies to serve as the "Marketing
            Committee", and the Marketing Committee shall meet within thirty
            (30) calendar days of the Effective Date. The Marketing Committee
            shall:

            2.2.1   Discuss preferred pricing for the Product and the strategy
                    for implementing such pricing, and develop the strategy for
                    marketing and distributing the Product in the Pediatric
                    Market in the Territory;

            2.2.2   Establish forecasted Pediatric Sales of Product for each
                    individual Sales Year in advance of such Sales Year, showing
                    anticipated Pediatric Sales for each calendar month during
                    such Sales Year;

            2.2.3   Establish Product promotion goals for the Pediatric Market
                    in the Territory and the preferred means to attain such
                    goals, and review and establish a plan for the distribution
                    of the Sepracor Promotional Materials and Abbott Product
                    Materials;

            2.2.4   Provide advice and guidance regarding budget, scope and
                    extent of the Abbott Promotional Efforts; provided, however,
                    Abbott shall make all strategic decisions with respect to
                    Abbott Promotional Efforts and budget for the Abbott
                    Promotional Efforts, which strategic decisions shall be
                    consistent with the terms of this Agreement;

            2.2.5   Provide advice and guidance regarding budget, scope, and
                    extent of the Sepracor training of Abbott Representatives;
                    provided, however, Abbott shall make all strategic decisions
                    with respect to training of Abbott Representatives (other
                    than with respect to the Initial Training), which decisions
                    shall be in accordance with the terms of this Agreement; and
                    further provided, however, Sepracor shall make all strategic
                    decisions with respect to training of Sepracor
                    Representatives;

            2.2.6   Serve as an advisory panel to address any matter either
                    Party brings before the Marketing Committee pursuant to the
                    terms and conditions of this Agreement;

            2.2.7   Meet at least once during each Sales Quarter to discuss
                    matters assigned to the Marketing Committee. Marketing
                    Committee

                                       8
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                    meetings shall be held at mutually agreed upon dates, times
                    and places, or by conference call;

            2.2.8   Serve as a conduit for the exchange of information and input
                    relating to the further development of the Product by
                    Sepracor pursuant to Section 4.1, for the purpose of
                    Sepracor seeking the Pediatric Bronchospasm Expanded
                    Approval; provided, however, that appropriate technical
                    personnel of each Party shall attend any Marketing Committee
                    meeting where subject matter relating to this Subsection
                    2.2.8 is on the meeting agenda; and

      2.3   Perform the tasks or functions specified in Section 1.31, Section
            1.32, Section 3.6.2, and Section 4.15. 2.

      Decisions of the Marketing Committee shall be by a vote of either four (4)
      to zero (0) or three (3) to one (1). In the event that such a decision
      cannot be reached on any matter or issue before the Marketing Committee,
      the matter or issue shall first be referred to a panel consisting of one
      (1) senior management designee from each Party. If the matter or issue is
      not decided by the panel, Sepracor shall unilaterally decide the matter or
      issue.

Article 3. ABBOTT PROMOTIONAL EFFORTS.

      3.1   Abbott Promotional Efforts.

      Abbott Promotional Efforts shall be as follows:

            3.1.1   Abbott Representatives. Abbott shall use its reasonable
                    commercial efforts to promote the Product to the Pediatric
                    Market for sale in the Territory through Abbott
                    Representatives [**]. With Sepracor's prior written
                    approval, which approval shall not be unreasonable withheld,
                    Abbott may carry out any of its Abbott Promotional Efforts
                    through Affiliates of Abbott or temporary contract
                    resources, which shall be bound by all terms and conditions
                    of this Agreement. Subject to the provisions of Section
                    12.4, commencing in December 1999, Abbott shall promote the
                    Product to the Pediatric Market in the Territory . Abbott
                    Promotional Efforts shall include:

                    3.1.1.1  Promotion to Pediatricians. Abbott shall use their
                             [**] pediatric sales force, including a minimum of
                             [**] Abbott Representatives[**], and Abbott
                             Representatives shall provide a minimum of [**] on
                             an [**] in the Pediatric Market ([**] will be part
                             of such [**] and will be [**]), wherein [**] of the
                             [**], and a minimum of [**] of the [**] in the
                             [**].

                    3.1.1.2  Promotion to Abbott Targeted Hospitals. Abbott
                             shall use [**] Abbott Representatives [**]
                             (referred to herein

                                       9
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                             as "Abbott [**] Representatives"), [**] Abbott
                             Targeted Hospitals, wherein at each such Abbott
                             Targeted Hospital, [**] is the [**] and such [**]
                             shall include [**] of the [**]. On an annual basis,
                             Abbott [**] Representatives shall provide a minimum
                             of [**] is the [**], and a minimum of [**] of the
                             [**] by Abbott [**] Representatives [**] in the
                             [**]. Additionally, from the Effective Date through
                             December 31, 2000, Abbott shall use reasonable
                             commercial efforts to utilize [**] its existing
                             Abbott Representatives who are academic specialty
                             representatives (referred to herein as "Abbott
                             Academic Representatives") [**] academic Abbott
                             Targeted Hospitals wherein at each such academic
                             Abbott Targeted Hospital, [**], and such [**] shall
                             include [**] of the [**]. Beginning January 1,
                             2001, Abbott shall use [**] Abbott Academic
                             Representatives [**] Abbott Targeted Hospitals. On
                             an annual basis, from the Effective Date through
                             December 31, 2000, Abbott shall use reasonable
                             commercial efforts to have Abbott Academic
                             Representatives [**] is the [**] and a minimum of
                             [**] of the [**] Abbott Academic Representatives
                             shall be [**] in the [**]. Beginning on January 1,
                             2001, on an annual basis, Abbott Academic
                             Representatives [**] is the [**] and a minimum of
                             [**] of the [**] Abbott Academic Representatives
                             shall be [**] in the [**].

            3.1.2   Calling Cycle and Call Tracking. In performing Abbott
                    Promotional Efforts, Abbott shall use reasonable commercial
                    efforts to ensure that the calling cycle of Abbott
                    Representatives during a Sales Year is distributed
                    throughout that Sales Year in a manner that reflects the
                    seasonality of the Approved Indications and the fluctuating
                    demand for Product during the course of the Sales Year. [**]
                    including [**], and will [**] on a [**]. Unless otherwise
                    agreed by the Parties [**] including [**], and [**] and
                    beginning [**] will [**] on a [**] with a [**]. Abbott, in
                    its discretion, may promote the Product through additional
                    Abbott Representatives from time to time, provided they
                    receive appropriate training with respect to promoting the
                    Product.

            3.1.3   Manner of Promotion Abbott shall perform Abbott Promotional
                    Efforts taking into consideration the advice, guidance and
                    decisions of the Marketing Committee, and Abbott shall
                    perform in accordance with all applicable federal, state and
                    local laws, rules, and regulations of the Territory,
                    including, but not limited to, the Federal Food, Drug and
                    Cosmetic Act. Abbott shall not be in default of any
                    obligation hereunder as a result of any administrative or
                    judicial determination

                                       10
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                    that either Sepracor Promotional Material or Sepracor's
                    advertisements for the Product violates:

                    3.1.3.1  The approved Product labeling; or

                    3.1.3.2  Any applicable federal, state or local laws, rules,
                             and regulations of the Territory.

            3.1.4   Distribution of Sepracor Promotional Materials. As part of
                    the Abbott Promotional Efforts, and in accordance with
                    Sections 5.3 and 5.4 hereof, Abbott Representatives shall
                    distribute Sepracor Promotional Materials to the Pediatric
                    Market, potential and existing Purchasers, and others to
                    whom the Abbott Representatives make Abbott Promotional
                    Efforts in the Territory.

            3.1.5   Compliance with Sampling Act. Abbott shall distribute
                    Samples only in strict conformance with the Sampling Act.

      3.2   Product Manager and Sales Force. Abbott shall assign a Product
            manager, who is an Abbott Representative, to oversee and manage the
            Abbott Promotional Efforts in the Territory. At all times during the
            Term, Abbott shall maintain a sales force of Abbott Representatives
            to promote the Product to the Pediatric Market throughout the
            Territory.

      3.3   Abbott Representative Training.

            3.3.1   Initial Training. Sepracor shall be responsible for the
                    Initial Training of the Abbott Representatives in the
                    co-promotion of the Product. The format and content of the
                    Initial Training shall be agreed upon by the Parties.
                    Initial Training will begin with home training of Abbott
                    Representatives in late November/early December 1999.
                    Sepracor shall also provide Initial Training to the Abbott
                    Representatives who are territory managers in December 1999,
                    and to Abbott Representatives at Abbott's regional sales
                    meetings during January 2000, at agreed upon times and
                    places. In addition, Sepracor shall provide training to
                    Abbott Representatives at Abbott's national sales meetings
                    in March 2000, at agreed upon times and places. Abbott shall
                    use its commercially reasonable efforts to ensure that all
                    Abbott Representatives who may initially promote the Product
                    attend the Initial Training. [**] at such training. For
                    purposes of Initial Training, Sepracor shall supply sales
                    force training materials in sufficient quantities to train
                    the Abbott Representatives. [**] with the printing of the
                    training materials for Initial Training of the Abbott
                    Representatives. Sepracor shall consult with Abbott
                    regarding the appropriate levels of sales force training
                    materials and shall assist Abbott in Abbott's initial
                    start-up efforts.

                                       11
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

            3.3.2   Additional Training. Following the Initial Training,
                    Sepracor shall provide training to and consult with the
                    Abbott Representatives on an on-going basis in the promotion
                    of the Products, upon mutual agreement of the Parties. The
                    Marketing Committee shall determine the frequency, scope and
                    attendees for subsequent training sessions. Subject to the
                    Marketing Committee's determination, such on-going training
                    shall include, but not be limited to, training sessions
                    [**] for purposes of remedial training, education on
                    current developments, new uses or indications, and new
                    Sepracor marketing materials or programs; the time
                    dedicated to, and the nature of, such training being
                    subject to approval by Abbott. Each Party shall [**]
                    agreed upon by the Parties. Abbott and Sepracor shall
                    [**] for such additional training of Abbott
                    Representatives.

      3.4   Abbott Representatives' Incentive Compensation. Abbott, in its sole
            discretion and at its expense, shall compensate the Abbott
            Representatives for promoting the Product in an appropriate manner
            to reflect individual Abbott Representative's efforts in performing
            the Abbott Promotional Efforts in the Territory; provided, however,
            that Abbott's compensation of Abbott Representatives, including
            compensation, incentive compensation, bonuses, and prizes, shall be
            consistent with Abbott satisfying its obligations under this
            Agreement. During the Term, Abbott, at its expense, shall award
            incentive compensation, bonuses or prizes to Abbott Representatives
            for achieving goals for volume of Product sales.

      3.5   Requests for Medical Information by Third Parties. In the event
            Abbott's Medical Affairs Liaison receives inquiries from third
            parties which relate to the efficacy, safety or other medical issues
            regarding the Product, Abbott's Medical Affairs Liaison shall direct
            such inquiries within two (2) business days of such Medical Affairs
            Liaison's receipt of such inquiry to Sepracor's Medical Affairs
            Liaison, unless such inquiry is of a routine nature and the response
            is clearly set forth in the Product labeling. Within a reasonable
            time period following the Effective Date, Sepracor's Medical Affairs
            Liaison shall supply Abbott's Medical Affairs Liaison with
            Sepracor's standard responses to questions of a routine nature
            directed to Sepracor with respect to the Product.

      3.6   Abbott Reports.

            3.6.1   Reports on Promotion Efforts. Subject to the provisions of
                    Section 12.4, not later than [**] days after the end of each
                    Sales Quarter during the Term, Abbott shall supply Sepracor
                    with a report summarizing the Abbott Promotional Efforts
                    during such period in a manner which

                                       12
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                    permits Sepracor to evaluate Abbott's compliance with its
                    obligations regarding Abbott Promotional Efforts [**] made,
                    [**] of the [**] during the Sales Quarter, unless otherwise
                    agreed by the Parties in writing.

            3.6.2   Format of Reports. The Marketing Committee shall determine
                    the format, content, and detail of reports required by this
                    Section.

      3.7   Other Abbott Costs and Expenses. Except as otherwise specifically
            stated in this Agreement, Abbott shall be solely and exclusively
            responsible for all costs and expenses relating to or arising from
            marketing, promotion (including distribution of Samples, Sepracor
            Promotional Materials, and Abbott Product Materials), and sale of
            Product incurred by Abbott, its Affiliates, and their employees and
            agents.

Article 4. SEPRACOR RESPONSIBILITIES AND PROMOTIONAL EFFORTS.

      4.1   Pediatric Expanded Approval. At its sole expense, Sepracor shall use
            good faith reasonable efforts in connection with the further
            development of the Product, including the conduct of clinical
            trials, for the purpose of obtaining Pediatric Bronchospasm Expanded
            Approval, and shall take all regulatory actions necessary to file
            the NDA or sNDA for such Pediatric Bronchospasm Expanded Approval by
            [**]

      4.2   Maintenance of Product NDA. During the Term, Sepracor shall use its
            reasonable commercial efforts to maintain, at Sepracor's sole cost
            and expense, all NDA's which the FDA has granted as of the Effective
            Date or during the Term.

      4.3   Product Formulations. Sepracor shall be solely responsible for the
            formulation, indications, labeling and packaging for the Product.
            Sepracor may change any formulation, labeling, and/or packaging at
            its own discretion with thirty (30) days prior written notice to
            Abbott, unless such change requires pre-approval by the FDA, in
            which case Sepracor shall obtain Abbott's prior written approval
            which shall be promptly given and not unreasonably withheld.
            Sepracor shall be responsible for the cost of such changes and the
            cost to change any and all Sepracor Promotional Materials.

      4.4   Regulatory Responsibilities. Subject to its obligations set forth in
            Sections 4.1 and 4.2, Sepracor shall have responsibility at its sole
            discretion for all regulatory submissions and other matters
            regarding the Product, including without limitation the Approved
            Indications, filing of all NDAs and other applications relating to
            the Product. Sepracor shall promptly communicate with Abbott
            regarding all significant matters communicated between Sepracor and
            the FDA that relate to the foregoing or to the promotion, sale or
            use of the Product.

                                       13
<PAGE>

CONFIDENTIAL

      4.5   Patent and Proprietary Protection. Sepracor shall have
            responsibility at its sole discretion for prosecuting and
            maintaining all patent applications and patents relating to the
            Product, as well as all trademark applications and trademarks
            relating to the Trademark and any other Sepracor Marks, service
            marks, copyrights and other intellectual property relating to the
            Product. Sepracor shall use its reasonable commercial efforts to (a)
            maintain in the Territory its patents and Sepracor Marks relating to
            the Product and (b) prosecute in good faith in the Territory its
            patent applications relating to the Product. Sepracor shall use its
            reasonable commercial efforts to enforce patents relating to the
            Product against Third Parties who infringe those patents in the
            Territory. Any compensatory damages derived from enforcement of any
            patents relating to Product shall be used to first reimburse
            Sepracor for its costs and expenses relating to such enforcement,
            with any remaining compensatory damages to be treated as Net Sales.
            A proportion of such Net Sales will be deemed Pediatric Sales
            subject to the Commission set forth in Section 7.1(a), and this
            proportion will be determined by calculating the average proportion
            of Pediatric Sales to Net Sales over the four Sales Quarters
            preceding the award of compensatory damages. Any punitive damages,
            exemplary damages, or other enhanced damages shall be retained
            solely by Sepracor.

      4.6   Consultation with Abbott. Sepracor agrees to consult with Abbott,
            upon Abbott's reasonable request, regarding regulatory matters,
            patent and trademark strategy, and other related matters to a
            reasonable extent to maximize Pediatric Sales; provided, however,
            that Sepracor shall retain responsibility for all such matters at
            its sole discretion as provided in this Article 4.

      4.7   Product Manufacture. Sepracor shall manufacture, or have
            manufactured, the Product, in accordance with cGMP and the
            specifications for the Product as approved by the FDA, and shall be
            responsible for all quality assurance issues arising therefrom.
            Sepracor shall be responsible for all manufacture, labeling,
            packaging and distribution of the Product in the Territory, and
            shall comply with all applicable federal laws, rules, and
            regulations regarding the same.

                                       14
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

      4.8   Complaints, Product Defects and Returns. Abbott shall notify
            Sepracor within two (2) business days of any Product complaints
            received by Abbott. As between Sepracor and Abbott, Sepracor shall
            be responsible for all manufacturing defects in Product. In
            addition, Sepracor shall be responsible for addressing all customer
            complaints regarding any alleged manufacturing defects of any
            Product. Sepracor shall be responsible for handling and covering the
            cost of all recalls and returns of Product and replacement of
            defective Product. Abbott, its Affiliates, officers, directors,
            employees or agents shall in no way be responsible for any defects
            or damages with respect to Product, or its shipment or delivery,
            provided, however, that Abbott shall be responsible for Samples
            delivered to Abbott from and after the time Abbott or its agents or
            representatives takes delivery of such Samples (except for defects
            in the Samples or packaging thereof present prior to delivery to
            Abbott).

      4.9   Product Supply. At all times during the Term, Sepracor shall sell
            and supply sufficient quantities of the Product to meet the
            requirements of Purchasers in the Pediatric Market in the Territory.
            Sepracor shall notify Abbott in writing of any Product manufacturing
            difficulties which cause or may cause shortages of Product within
            fifteen (15) business days of Sepracor's becoming aware of such
            manufacturing difficulties. If Sepracor is unable to fill in a
            timely manner all orders for Product in the Pediatric Market in the
            Territory because a

            Product is out of stock, Sepracor shall distribute available Product
            among all customers on a fair and practical basis, keeping in mind
            the best interests of the Parties. Sepracor shall immediately notify
            Abbott if Sepracor anticipates delays in the shipment of Product to
            Purchasers.

      4.10  Sepracor Promotional Efforts.

            Sepracor Promotional Efforts shall be as follows:

            4.10.1  Sepracor Representatives. Sepracor shall use its reasonable
                    commercial efforts to promote the Product to the Pediatric
                    Market for sale in the Territory through the Sepracor
                    Representatives. Notwithstanding anything to the contrary in
                    this Agreement, the Parties agree that Sepracor and the
                    Sepracor Representatives retain the right to promote the
                    Product to Abbott Targeted Hospitals, [**] pediatricians
                    prescribing albuterol (referred to herein as [**]) in the
                    Territory, and to any other portion of the Pediatric Market
                    that Abbott and Sepracor may mutually agree upon, it being
                    agreed that Abbott and Abbott Representatives shall have the
                    sole right to promote the Product to pediatricians other
                    than those in the [**] in the Territory and the co-exclusive
                    right to promote the Product to Abbott Targeted Hospitals
                    and pediatricians in the [**] in the Territory.

                                       15
<PAGE>

CONFIDENTIAL

            4.10.2  Continued Promotional Activity. Sepracor shall promote
                    Product during the Term in the Territory at least as
                    diligently as it had prior to the Effective Date; provided,
                    however, that Sepracor shall be permitted to cease any and
                    all contract sales force activity at its sole discretion.
                    During the Term, Sepracor shall advertise the Product for
                    Approved Indications to the Pediatric Market in the
                    Territory in substantially the same manner as Sepracor
                    advertised the product prior to the Effective Date,
                    including, but not limited to, continuing to place
                    advertisements in quality medical journals.

            4.10.3  Manner of Promotion. Sepracor shall perform Sepracor
                    Promotional Efforts taking into consideration the advice,
                    guidance and decisions of the Marketing Committee, and
                    Sepracor shall perform in accordance with all applicable
                    federal, state and local laws, rules, and regulations of the
                    Territory, including, but not limited to, the Federal Food,
                    Drug and Cosmetic Act. Sepracor shall be responsible for and
                    shall indemnify Abbott, its Affiliates, officers, directors,
                    employees and agents, in accordance with and subject to
                    Section 14.1, for any liability or expense that may arise as
                    a result of any administrative or judicial determination
                    that either a Sepracor Promotional Material or Sepracor's
                    advertising for the Product to the Pediatric Market in the
                    Territory violates:

                    4.10.3.1 The approved Product labeling; or

                    4.10.3.2 Any applicable federal, state or local laws, rules,
                             and regulations of the Territory.

            4.10.4  Distribution of Sepracor Promotional Materials. Sepracor
                    Representatives shall distribute Sepracor Promotional
                    Materials to potential and existing Purchasers of Product
                    and others to whom the Sepracor Representatives promote the
                    Product.

            4.10.5  Compliance with Sampling Act. Sepracor shall distribute
                    Samples only in strict conformance with the Sampling Act.

      4.11  Product Manager. Sepracor shall assign a Product manager, who is a
            Sepracor Representative, to oversee and manage the Sepracor
            Promotional Efforts in the Territory

      4.12  Sepracor Representative Training. Sepracor shall be responsible for
            the training of all Sepracor Representatives in the co-promotion of
            the Product. Sepracor shall supply, at Sepracor's cost, sales force
            training materials to train the Sepracor Representatives.

            Sepracor shall continue to train and consult with the Sepracor
            Representatives on an on-going basis in the promotion of the
            Products.

                                       16
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

      4.13  Sepracor Representatives' Incentive Compensation. Sepracor, in its
            sole discretion and at its expense, shall compensate the Sepracor
            Representatives for promoting the Product in an appropriate manner
            to reflect individual Sepracor Representatives efforts in promoting
            the Product in the Territory. Sepracor, at its expense, shall award
            incentive compensation, bonuses or prizes to Sepracor
            Representatives for achieving goals for volume of Product sales.

      4.14  Requests for Medical Information by Third Parties. In the event
            Sepracor's Medical Affairs Liaison receives inquiries from third
            parties which relate to the efficacy, safety or other medical issues
            regarding the Product, Sepracor's Medical Affairs Liaison shall
            prepare standard responses to questions of a routine nature directed
            to Sepracor with respect to the Product and shall use the standard
            responses in addressing inquiries.

      4.15  Sepracor Reports.

            4.15.1  Reports on Promotion Efforts. Subject to the provisions of
                    Section 12.4, not later than [**] days after the end of each
                    Sales Quarter during the Term, Sepracor shall supply Abbott
                    with a report summarizing the Sepracor Promotional Efforts
                    to the Pediatric Market in the Territory during such period.

            4.15.2  Format of Reports. The Marketing Committee shall determine
                    the format, content, and detail of reports required by this
                    Section.

            4.15.3  Pediatric Sales Tracking. Within [**] days of Sepracor's
                    receipt, after each applicable Sales Quarter, of all data
                    from external sources necessary to calculate the Commission,
                    Sepracor shall provide to Abbott (a) total gross invoice
                    amount of Product for the Sales Quarter, (b) total Net Sales
                    for the Sales Quarter, and (c) a reconciliation of Net Sales
                    to Pediatric Sales for the Sales Quarter. In addition, for
                    each Sales Year, within [**] days of Sepracor's receipt,
                    after the fourth Sales Quarter in a Sales Year, of all data
                    from external sources necessary to calculate the Commission,
                    Sepracor shall provide to Abbott a reconciliation of total
                    gross invoiced amount to Net Sales (including total amounts
                    for each of the components set forth in Section 1.28 used by
                    Sepracor in calculating Net Sales from the total gross
                    invoiced amount) for each Sales Quarter in the Sales Year.

      4.16  Other Sepracor Costs and Expenses. Except as otherwise specifically
            stated in this Agreement, Sepracor shall be solely and exclusively
            responsible for all costs and expenses relating to or arising from
            marketing, promotion (including distribution of Samples, Sepracor
            Promotional Materials, and Abbott Product Materials), and sale of
            Product incurred by Sepracor, its Affiliates, and their employees
            and agents.

                                       17
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

Article 5. LABELING, SAMPLING AND PROMOTIONAL MATERIALS.

      5.1   Product Labeling. All Product labeling decisions shall be made by
            Sepracor, and Sepracor shall have sole responsibility therefor.
            Product labels and packaging shall not bear any Abbott Marks or any
            other Abbott identifying material.

      5.2   Sampling. Except as otherwise provided in this Agreement, Sepracor,
            [**], shall produce all Samples for use in the promotion of the
            Product. Samples shall be marked "Sample - Not for Sale."
            Sepracor shall establish the guidelines for sampling, and
            shall consult with Abbott with respect thereto. Sepracor shall
            supply such quantities of Samples to Abbott as Abbott and Sepracor
            mutually agree is appropriate in connection with Abbott Promotional
            Efforts. Each party shall bear its own cost of distribution of
            Samples to the Pediatric Market. Sepracor shall [**] to the
            production of [**]. [**] from any [**] for the [**]; provided,
            however, [**] shall not be [**] during any 12-month period (from
            April through March) thereafter; and, provided further, in the [**]
            pursuant to [**] for the first twelve (12) months. Abbott shall
            track Sample distribution and provide to Sepracor all reports
            relating the sampling that Sepracor may require in order to comply
            with applicable laws, rules, or regulations.

      5.3   Development of Sepracor Promotional Materials. Except as otherwise
            provided in this Agreement, Sepracor, at its cost and expense
            (including any agency fees), shall develop Sepracor Promotional
            Materials for Abbott's use in the promotion of the Product. Sepracor
            shall consult with Abbott with respect to the development of
            Sepracor Promotional Materials. Abbott shall have an opportunity to
            review the Sepracor Promotional Materials and make suggestions
            regarding format and content. Abbott shall provide Sepracor with any
            objections to or suggestions regarding format or content of Sepracor
            Promotional Materials for Abbott's use within thirty (30) calendar
            days of delivery to Abbott of any proposed Sepracor Promotional
            Materials. If in the opinion of Abbott's counsel any Sepracor
            Promotional Material may conflict with any law, rule or regulation
            in the Territory, and if Abbott so informs Sepracor in writing
            within the thirty (30) day period, Abbott shall not be required to
            distribute or pay any share of expenses relating to such Sepracor
            Promotional Material. If Abbott does not notify Sepracor within the
            thirty (30) day period, the Parties shall [**] the direct
            out-of-pocket costs of printing and reprinting any Sepracor
            Promotional Materials for distribution by Abbott's Representatives.
            In any event, Abbott Representatives shall not be required to
            distribute Sepracor Promotional Materials which, in the opinion of
            Abbott's counsel, conflicts with any law, rule or regulation in the
            Territory.

      5.4   Distribution of Sepracor Promotional Materials. In connection with
            the Abbott Promotional Efforts, Abbott Representatives shall
            distribute Sepracor Promotional Materials to the Pediatric Market.
            Sepracor shall consult with

                                       18
<PAGE>

CONFIDENTIAL

            Abbott with respect to the distribution of Sepracor Promotional
            Materials. Sepracor shall supply such quantities of Sepracor
            Promotional Materials to Abbott as Abbott and Sepracor mutually
            agree is appropriate in connection with Abbott Promotional Efforts.

      5.5   Identification of Abbott on Sepracor Promotional Materials. During
            the Term and subject to the provisions of this Agreement, Abbott
            Marks and Sepracor trade names and logos shall be jointly presented
            on Sepracor Promotional Materials and Sepracor's advertising of the
            Product for the Pediatric Market in the Territory. Certain Abbott
            Marks, as agreed in writing by the parties, shall be displayed on
            all Sepracor Promotional Materials (other than such materials in
            existence as of the Initial Training date of Abbott Representatives)
            for distribution by Abbott Representatives with substantially equal
            prominence and frequency as Sepracor's trade names and logos.
            Sepracor shall not distribute any printed promotional materials
            relating to pediatric use of Product, other than Sepracor
            Promotional Materials, to the Pediatric Market in the Territory.

            5.5.1   Limited License to Abbott Marks. Abbott hereby grants to
                    Sepracor a limited non-exclusive license, without payment of
                    any royalty or licensing fees, to the Abbott Marks solely
                    for the purposes of developing, producing, and using the
                    Sepracor Promotional Materials for the Product and
                    advertisements for the Product to the Pediatric Market in
                    the Territory during the Term, and in accordance with the
                    terms of this Agreement.

            5.5.2   Sepracor's Use of Abbott Marks. All uses of the Abbott Marks
                    shall be approved in advance by Abbott. Abbott shall retain
                    all rights to the Abbott Marks and Abbott's copyrights,
                    trademarks, and logos, which shall remain Abbott's sole
                    property, free of any claims thereon or thereto by Sepracor.
                    Sepracor agrees that all Product advertising bearing the
                    Abbott Marks shall contain appropriate legends, markings and
                    notices as mutually agreed upon by the Parties. Sepracor
                    shall place the following legend "___ is a trademark of
                    Abbott Laboratories" on each Product or Promotional Material
                    which bears the Abbott Marks.

            5.5.3   Abbott's Retention of Rights to the Abbott Marks. All
                    goodwill associated with the Abbott Marks inure solely to
                    the benefit of Abbott. Sepracor shall notify Abbott in
                    writing of any infringements or imitations by third parties
                    of the Abbott Marks which may come to Sepracor's attention.

            5.5.4   Discontinuation of Use of Abbott Marks. Upon termination or
                    expiration of this Agreement, Sepracor shall discontinue all
                    use of the Abbott Marks

                                       19
<PAGE>

CONFIDENTIAL

            5.6   Abbott Product Materials. In addition to Sepracor Promotional
                  Materials developed and prepared by Sepracor, Abbott may
                  develop, at its expense, Abbott Product Materials, to be used
                  by Abbott in connection with Abbott Promotional Efforts. Prior
                  to distribution to Abbott Representatives or others, Abbott
                  shall give Sepracor the opportunity to review the Abbott
                  Product Materials and make suggestions regarding format and
                  content, and shall not print or distribute any Abbott Product
                  Materials prior to receiving Sepracor's written approval.
                  Sepracor shall use reasonable efforts to review and approve
                  the Abbott Product Materials within thirty (30) days after
                  receipt of proposed Abbott Product Materials. Sepracor shall
                  submit any such Abbott Product Material to FDA, as may be
                  required by law or regulation. In the event of any change to
                  any Product formulation, labeling, or packaging which requires
                  a change in any Abbott Product Materials, after notice from
                  Sepracor of any such change, Abbott shall revise, and receive
                  Sepracor's approval on all such revisions, on all Abbott
                  Product Materials affected by such change before any further
                  distribution of any affected Abbott Product Materials. The
                  cost and expense of modifications to Abbott Product Materials
                  shall be borne by Abbott. Abbott shall retain all rights,
                  including copyrights, to the Abbott Product Materials, except
                  with respect to any Sepracor Marks, which shall remain
                  Sepracor's sole property, free of any claims thereto by
                  Abbott. Abbott shall use any Abbott Product Materials
                  containing the Trademark or Sepracor Marks only in connection
                  with the promotion of the Product to the Pediatric Market in
                  the Territory. Abbott shall have no obligation to pay any
                  royalties or other compensation to Sepracor on the use of the
                  Sepracor Marks used in the Abbott Product Materials. During
                  the Term, Sepracor may use, at its expense, the Abbott Product
                  Materials in connection with Sepracor's promotion of the
                  Product to the Pediatric Market in the Territory. After the
                  Term, Sepracor shall have a royalty-free non-exclusive license
                  to use Abbott Product Materials, exclusive of any Abbott Marks
                  or any other Abbott intellectual property that may appear or
                  is described therein, and to make and use derivative works
                  thereof.

            5.7   Identification of Sepracor on Abbott Product Materials. During
                  the Term and subject to the provisions of this Agreement,
                  Abbott Marks and Sepracor Marks shall be jointly presented on
                  Product advertising developed by Abbott and Abbott Product
                  Materials. Sepracor Marks shall be displayed on all Abbott
                  Product Materials with substantially equal prominence as
                  Abbott Marks.

                  5.7.1 Limited License to Sepracor Marks. Sepracor hereby
                        grants to Abbott a limited non-exclusive license,
                        without payment of any royalty or licensing fees, to
                        Sepracor Marks, solely for the purposes of developing,
                        producing, using the Abbott Product Materials for the
                        Product and advertisements for the Product to the
                        Pediatric Market in the Territory during the Term, and
                        in accordance with the terms of this Agreement.

                                       20
<PAGE>

CONFIDENTIAL

                  5.7.2 Abbott's Use of Sepracor Marks. All uses of the Sepracor
                        Marks by Abbott shall be approved in advance by
                        Sepracor. Sepracor shall retain all rights to Sepracor
                        Marks, and Sepracor's copyrights, trademarks, and logos,
                        which shall remain Sepracor's sole property, free of any
                        claims thereon or thereto by Abbott. Abbott agrees that
                        all Product bearing the Sepracor Marks shall contain
                        appropriate legends, markings and notices as mutually
                        agreed upon by the Parties. Abbott shall place the
                        following legend "___ is a trademark of Sepracor Inc."
                        on each item which bears the Sepracor Marks.

                  5.7.3 Sepracor's Retention of Rights to the Sepracor Marks.
                        All goodwill associated with the Sepracor Marks inure
                        solely to the benefit of Sepracor. Abbott shall notify
                        Sepracor in writing of any infringements or imitations
                        by third parties of the Sepracor Marks which may come to
                        Abbott's attention.

                  5.7.4 Discontinuation of Use of Sepracor Marks. Upon
                        termination or expiration of this Agreement, Abbott
                        shall discontinue all use of the Sepracor Marks.

Article 6. PRICING, QUOTATIONS, ORDERS, BILLING, COLLECTION AND SALES TRACKING.

      6.1   Pricing. Sepracor shall consider the recommendations of the
            Marketing Committee in developing strategies for the pricing, sale
            and distribution of Product for the Pediatric Market in the
            Territory. Sepracor shall, in its sole discretion, determine prices
            and terms of sale to Purchasers for Product, and may change such
            prices following at least thirty (30) days prior written notice to
            Abbott. Abbott shall not change any pricing or grant any discounts
            or rebates on any Product without the prior written consent of
            Sepracor.

      6.2   Pricing and Rebate Contracts. Sepracor shall be a party and
            signatory to any and all pricing and rebate contracts with
            Purchasers for or regarding the sale of Product.

      6.3   Quotations and Orders; Billing and Collection. Sepracor shall have
            sole responsibility for the preparation and delivery of all
            quotations and offers of prices hereunder, for the acceptance and
            fulfillment of all orders, and for the

            Confidential Materials omitted and filed separately with the
            Securities and Exchange Commission. Asterisks denote omissions.

      6.4   invoicing and collection of amounts due from Purchasers. Sepracor
            shall use reasonable efforts in its collection activities.

      6.5   Electronic Database. Sepracor shall utilize a computerized system
            accurately to account for all Product orders and assist with Net
            Sales tracking as set forth in Section 4.15.3. The system shall be
            capable of reporting: (a) gross invoiced dollar and unit sales on a
            daily basis, (b) Net Sales on a monthly basis, and (c) the
            components of the reconciliation of total gross invoiced amounts to
            Net

                                       21
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

            Sales and Net Sales to Pediatric Sales. Sepracor shall assure
            appropriate back-up and information storage for its system.

Article 7. COMPENSATION TO ABBOTT.

      7.1   Commission. (a) In consideration of Abbott's efforts hereunder,
            Sepracor shall pay Abbott a Commission on Pediatric Sales in
            accordance with this Article 7. The Commission shall be based upon
            Pediatric Sales of Product for each Sales Year in the Territory
            using the following incremental Commission rates: (i) on those
            annual Pediatric Sales up to and including [**], the commission rate
            is [**]; (ii) on the incremental annual Pediatric Sales over [**]
            and up to and including [**], the commission rate is [**]; and (iii)
            on the incremental annual Pediatric Sales over [**], the commission
            rate is [**].

            (b)   Commencing April 1, 2000, and ending June 30, 2001, if the
                  Commission received by Abbott in any Sales Quarter does not
                  exceed [**], Sepracor shall reimburse the difference between
                  [**] and the Commission received by Abbott for such Sales
                  Quarter. The calculation and payment of such difference shall
                  occur within fifteen (15) days of Sepracor's receipt, after
                  each applicable Sales Quarter, of all data from external
                  sources necessary to calculate the Commission.

      7.2   Commission Payment. Sepracor shall pay the Commission for each Sales
            Quarter on or prior to [**] days after Sepracor's receipt, after
            each applicable Sales Quarter, of all data from external sources
            necessary to calculate the Commission .

      7.3   Audit. If Abbott, in its reasonable judgment, determines that an
            audit of Sepracor's relevant books and records is necessary to
            verify Pediatric Sales of Product, then upon notice to Sepracor
            Abbott shall have the right, at Abbott's cost and expense, to have a
            nationally recognized independent certified public accounting firm
            reasonably acceptable to Sepracor perform an audit of all relevant
            books and records of Sepracor for the sole purpose of verifying the
            Commissions payable as provided in this Agreement for no more than
            the three preceding years; provided, however, that as part of any
            audit on behalf of Abbott, Abbott's auditors must rely on Sepracor's
            independent certified public accounting firm as to the details and
            underlying data utilized in the calculation of Net Sales, although
            Abbott's auditors may review the details of the calculation of Net
            Sales from gross invoice amounts for the sole purpose of verifying
            the reasonableness of such calculation and to determine whether the
            calculation is consistent with the terms of Section 1.28 of this
            Agreement. Any such audit shall be conducted during Sepracor's
            normal business hours, at Sepracor's facilities, at a mutually
            agreed upon date and time. This right may not be exercised more than
            once in any calendar year, and once a calendar year is audited it
            may not be reaudited, provided that if there is a material disputed
            issue as to any audited year, such year, the two (2) preceding years
            and any

                                       22
<PAGE>

CONFIDENTIAL

            subsequent year may be reaudited solely as to material disputed
            issue until such time as the dispute is resolved. An issue shall be
            deemed to be a material disputed issue if it results in an
            underpayment of Commission to Abbott for the period under review of
            more than five percent (5%). The independent certified public
            accounting firm shall disclose to Abbott only information relating
            solely to the accuracy of the Commission provided to Abbott and
            Commission Payments made to Abbott under this Agreement, and such
            information shall be subject to the provisions of Article 15. If
            such audit reveals that Sepracor has under-reported aggregate annual
            Pediatric Sales to Abbott: (a) by five percent (5%) or less,
            Sepracor shall pay all past due Commissions within thirty (30) days
            following completion of the audit, or (b) by more than five percent
            (5%), Sepracor shall pay all past due Commissions plus interest
            thereon at the rate of ten percent (10.0%) simple interest per
            annum, plus all reasonable costs of Abbott's audit, within thirty
            (30) days following completion of the audit.

Article 8. MEDICAL INQUIRIES; NOTIFICATION OF ADVERSE DRUG EXPERIENCE.

      8.1   Communication. Within thirty (30) days after the Effective Date,
            each Party shall appoint its Medical Affairs Liaison to communicate
            with the other with regard to information required pursuant to this
            Article 8. Either Party may change its Medical Affairs Liaison by
            notice to the other Party. Sepracor shall be solely responsible for
            (a) addressing all medical inquiries from Purchasers and Abbott
            Representatives with respect to side effects of the Product, (b)
            investigating any adverse drug experience or adverse event matters,
            and (c) reporting any adverse drug experience to the FDA.

      8.2   Notification. During the Term, Abbott shall give Sepracor notice as
            set forth in this Section 8.2 of any adverse drug experience, as
            defined in 21 C.F.R. ss. 314.80, associated with the Product as to
            which Abbott obtains information in accordance with the following:

            8.2.1   Any adverse drug experience information obtained by Abbott
                    shall be reported to Sepracor's Medical Affairs Liaison, by
                    telephone or by facsimile within three (3) working days
                    after Abbott's initial receipt of any such information;
                    provided, however, any report of a serious unlabeled event
                    or any report of a death shall be reported by telephone and
                    facsimile to Sepracor's Medical Affairs Liaison within
                    twenty-four (24) hours after Abbott's receipt of the
                    information;

            8.2.2   Abbott shall maintain a record of the adverse drug
                    experience reports received by Abbott to assist Sepracor in
                    complying with 21 C.F.R. ss. 314.80 , including:

                    8.2.2.1 A copy of the drug experience report;

                                       23
<PAGE>

CONFIDENTIAL

                    8.2.2.2 The date the report was received; and

                    8.2.2.3 The date the report was provided to Sepracor.

            8.2.3   Sepracor shall keep Abbott reasonably informed of adverse
                    drug experience, as defined in 21 C.F.R. ss. 314.80,
                    associated with the Product in a manner and with details
                    sufficient to facilitate Abbott's performance hereunder.

            8.2.4   Sepracor will provide Abbott with a copy of quarterly safety
                    reports for Product and fifteen-day alert reports for
                    Product which Sepracor reports to the FDA.

      8.3   Product Report. If, during the Term, Sepracor determines it is
            necessary to issue a report to Sepracor Representatives with respect
            to the medical efficacy or side effects of the Product, Sepracor
            shall also provide such report to Abbott's Medical Affairs Liaison
            within two (2) business days of its issuance to the Sepracor
            Representatives, which report Abbott shall immediately distribute to
            Abbott Representatives.

      8.4   Product Recall. In the event any Product is recalled by the FDA or
            Sepracor in the Territory, Sepracor shall be responsible for all
            expenses relating to such recall and for all activities to be
            performed relating to such recall. Prior to any such recall,
            Sepracor shall advise Abbott of the situation. Sepracor shall
            provide Abbott with a prepared statement, subject to Abbott's
            approval, for use in response to inquiries regarding the Product
            recall which Abbott shall provide to Abbott Representatives
            promoting the Product. Abbott and the Abbott Representatives and
            Sepracor and the Sepracor Representatives shall use such prepared
            statement to respond to any inquiries received with regard to the
            Product recall and shall not make any other statement regarding the
            recall.

Article 9. OTHER PRODUCTS.

      9.1   Product Rights Ex-U.S. In the event Sepracor desires to have an
            entity other than Sepracor, or a Sepracor Affiliate market, sell,
            distribute, or promote the Product to the Pediatric market in any
            country outside the Territory, Sepracor shall give Abbott first
            notice of the opportunity to have Abbott market, sell, distribute,
            promote, co-promote or co-market the Product to the Pediatric Market
            in such country through aright of first negotiation for not more
            than thirty (30) calendar days after Sepracor's notice to Abbott
            hereunder.

      9.2   Product Rights to Geriatric Market. In the event Sepracor desires to
            have an entity other than Sepracor or a Sepracor Affiliate market,
            sell, distribute, or promote the Product specifically for use by the
            Geriatric Market in the Territory (and, if Abbott and Sepracor enter
            into any agreement with respect to the Geriatric Market in the
            Territory, in any country outside the Territory), Sepracor shall
            give Abbott first notice of the opportunity to have Abbott market,
            sell, distribute, promote, co-promote or co-market the Product for
            use by the

                                       24
<PAGE>

CONFIDENTIAL

            Geriatric Market in the Territory (and, if Abbott and Sepracor enter
            into any agreement with respect to the Geriatric Market in the
            Territory, in such country outside the territory) through a right of
            first negotiation for not more than thirty (30) calendar days after
            Sepracor's notice to Abbott hereunder.

      9.3   Rights of Negotiation for Other Products. In the event that Sepracor
            markets a pharmaceutical product containing levalbuterol as an
            active ingredient other than Product (meter-dose inhaler or CFC-free
            pulmonary formulation; oral formulation of the Product), or a
            pharmaceutical product containing R,R-formoterol as an active
            ingredient, for the Pediatric Market in the Territory, and Sepracor
            desires to have an entity other than Sepracor or a Sepracor
            Affiliate market, co-market, sell, distribute, promote or co-promote
            such pharmaceutical product to the Pediatric Market in the
            Territory, Sepracor shall provide notice ("Other Product Notice) to
            Abbott prior to any discussions with or proposals to any party other
            than Sepracor's Affiliates, and Abbott shall have a right of first
            negotiation with respect to the rights to market, co-market, sell,
            distribute, promote or co-promote such pharmaceutical product to the
            Pediatric Market in the Territory through a right of first
            negotiation for not more than thirty (30) calendar days after
            Sepracor's notice to Abbott hereunder. As of the date of the Other
            Product Notice, Sepracor shall make available to Abbott the
            following information relating to the product identified in the
            Other Product Notice: development plan; patent applications and
            other patent information; relevant material portions of FDA
            submissions; summary clinical trial and study information or final
            study reports, where appropriate.

Article 10. REPRESENTATIONS AND WARRANTIES; COVENANTS.

      10.1  Mutual Representations and Warranties. Each Party hereby represents
            and warrants to the other Party as of the Effective Date that:

            10.1.1  Such Party has the full power and authority to enter into
                    and perform this Agreement;

            10.1.2  The person(s) signing this Agreement on its behalf has been
                    properly authorized and empowered to enter into this
                    Agreement; and

            10.1.3  No consents or approvals which such Party has not previously
                    obtained are necessary for such Party to enter into this
                    Agreement and perform all of such Party's obligations
                    hereunder.

      10.2  Abbott Covenants. Abbott hereby covenants during the Term that:

            10.2.1  This Agreement shall not conflict with any other Abbott
                    contractual obligation.

            10.2.2  Abbott shall perform its obligations hereunder in accordance
                    with all applicable federal, state and local laws, rules,
                    and regulations of the Territory; provided, however, Abbott
                    shall not be in default of the

                                       25
<PAGE>

CONFIDENTIAL

                    terms and conditions of this Agreement if Abbott violates
                    any applicable federal, state or local laws, rules or
                    regulations in the Territory as a result of Abbott's use of
                    or reliance on the Sepracor Promotional Materials, Sepracor
                    Product labeling, Sepracor Product advertising or use of
                    Sepracor Marks.

            10.2.3  Abbott shall not take any action or fail to take any action
                    which is in conflict with any of the representations and
                    warranties made by Abbott in Sections 10.1 and 10.3.

            10.2.4  All uses of the Abbott Marks in Sepracor Promotional
                    Materials or Abbott Product Materials shall not violate any
                    applicable laws, rules, and regulations in the Territory.

            10.2.5  Abbott, and its agents or representatives shall maintain
                    adequate insurance to cover any loss or damage with regard
                    to Samples in the possession of Abbott, or its agents or
                    representatives.

            10.2.6  Abbott, and its agents or representatives shall ensure that
                    inventory of Samples in the possession of Abbott, or its
                    agents or representatives, is properly managed to ensure
                    that Samples are distributed on a first-in, first-out basis.

      10.3  Other Abbott Representations and Warranties. Abbott hereby
            represents and warrants to Sepracor, as of the Effective Date that:

            10.3.1  Abbott is the sole and exclusive owner of all right, title
                    and interest in and to the Abbott Marks.

            10.3.2  To the best of Abbott's knowledge, as of the Effective Date,
                    there are no patents or trademarks owned by third parties
                    which would be infringed by the manufacture, marketing,
                    sale, distribution, import, export or use of Abbott Marks in
                    the Territory.

            10.3.3  There are no suits, claims, or proceedings pending against
                    Abbott or any of its Affiliates in any court or by or before
                    any governmental body or agency with respect to Abbott Marks
                    which may limit any Sepracor Promotional Efforts or Abbott
                    Promotional Efforts or create any liability to Sepracor; and
                    to the best of Abbott's knowledge, no such actions, suits,
                    or claims have been threatened against Abbott or any of
                    Abbott's Affiliates.

            10.3.4  Prior to the Effective Date, Abbott has not entered into any
                    agreement which could limit Abbott in the performance of
                    their obligations under this Agreement.

            10.3.5  Prior to the Effective Date, Abbott has not received any
                    notice from the FDA of any violation of the Sampling Act or
                    any other law, rule or

                                       26
<PAGE>

CONFIDENTIAL

                    regulation which could limit Sepracor or Abbott in the
                    performance of their respective obligations under this
                    Agreement.

      10.4  Other Sepracor Representations and Warranties. Sepracor hereby
            represents and warrants to Abbott, as of the Effective Date that:

            10.4.1  Sepracor has the sole and exclusive right to market, promote
                    and sell, or license others to market, promote and sell, the
                    Product under the Trademark within the Territory.

            10.4.2  To the best of Sepracor's knowledge, as of the Effective
                    Date, there are no patents or trademarks owned by Third
                    Parties which would be infringed by the manufacture,
                    marketing, sale, distribution, import, export or use of the
                    Product or its Trademark in the Territory, and Sepracor has
                    not received any notification from a Third Party claiming
                    that the manufacture, marketing, sale, distribution, import,
                    export or use of the Product or its Trademark in the
                    Territory would infringe a patent or trademark owned by a
                    Third Party.

            10.4.3  There are no suits, claims, or proceedings pending against
                    Sepracor or any of its Affiliates in any court or by or
                    before any governmental body or agency with respect to the
                    Product, the Trademark or Sepracor marks which may limit any
                    Abbott Promotional Efforts or create any liability to
                    Abbott; and to the best of Sepracor's knowledge, no such
                    actions, suits, or claims have been threatened against
                    Sepracor or any of Sepracor's Affiliates.

            10.4.4  Sepracor has obtained and is the owner of the NDA for the
                    Approved Indication under Section 1.11.1 and Sepracor's
                    officers have no knowledge of any pending FDA actions to
                    revoke or withdraw such Approved Indication under the NDA.

                                       27
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

            10.4.5  Sepracor's net sales of the Product in the Territory in
                    calendar year 1999 through September 30, 1999, were
                    approximately [**].

            10.4.6  Prior to the Effective Date, except as set forth in Schedule
                    10.4.6, Sepracor has not entered into any agreement
                    regarding the Product which could limit Sepracor or Abbott
                    in the performance of their respective obligations under
                    this Agreement.

            10.4.7  Prior to the Effective Date, except as set forth in Schedule
                    10.4.7, Sepracor has not received any notice from the FDA of
                    any violation of the Sampling Act or any other law, rule or
                    regulation which could limit Sepracor or Abbott in the
                    performance of their respective obligations under this
                    Agreement;

            10.4.8  Sepracor is the sole and exclusive owner of all right, title
                    and interest in and to the Sepracor Marks.

      10.5  Sepracor Covenants. Sepracor hereby covenants during the Term that:

            10.5.1  This Agreement shall not conflict with any other Sepracor
                    contractual
                    obligation.

            10.5.2  Sepracor shall perform its obligations hereunder in
                    accordance with all applicable federal, state and local
                    laws, rules and regulations of the Territory; provided,
                    however, Sepracor shall not be in default of the terms and
                    conditions of this Agreement if Sepracor violates any
                    applicable federal, state or local laws, rules or
                    regulations in the Territory as a result of Sepracor's use
                    of or reliance on the Abbott Product Materials, Abbott
                    Product advertising or use of Abbott Marks.

            10.5.3  Sepracor shall manufacture or have manufactured the Product
                    in accordance with cGMP, Product specifications, all FDA
                    approved labeling, and all other applicable federal, state
                    and local laws, rules and regulations.

            10.5.4  Sepracor shall prepare keep and maintain its financial
                    statements and related schedules and records in accordance
                    with Generally Accepted Accounting Principles (GAAP).

            10.5.5  Sepracor shall not take any action or fail to take any
                    action which is in conflict with any of the representations
                    and warranties made by Sepracor in Section 10.1 or 10.4.

            10.5.6  Sepracor's database referenced in Section 6.4 shall not be
                    damaged or corrupted as a result of the passage of time from
                    December 31, 1999 to January 1, 2000.

                                       28
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

            10.5.7  All uses of the Sepracor Marks in Sepracor Promotional
                    Materials and Abbott Product Materials shall not violate any
                    applicable laws, rules and regulations in the Territory.

Article 11. INDEPENDENT CONTRACTOR RELATIONSHIP. The parties agree that they are
independent contractors. Neither party nor any employee of such party is an
employee, officer, agent, partner, business representative, or legal
representative of, or joint venturer with, the other party. Neither party has
authority to assume any obligation on behalf of the other party and shall not
hold out to third parties that it has any authority to do so; thus, neither
party shall take any action that might mislead or confuse third parties in this
regard. Unless otherwise provided herein, each party shall be responsible for
its own expenses and shall not incur expenses for the other party's account
unless expressly authorized in writing to do so by the other party.

Article 12. TERM AND TERMINATION.

      12.1  Initial Term. This Agreement shall commence as of the Effective Date
            and shall continue for a period of six (6) years from January 1,
            2000 ("Initial Term"):

            12.1.1  Subject to extension for an additional twelve (12) months
                    (the "Extension Term") in the event Pediatric Bronchospasm
                    Expanded Approval does not occur before [**]; and

            12.1.2  Subject to any earlier termination of the Initial Term or
                    any Extension Term as set forth in Section 12.2 or Section
                    12.3.

      12.2  Early Termination by Abbott. This Agreement may be terminated by
            Abbott upon written notice to Sepracor prior to the expiration of
            the Term or the Extension Term in the event:

            12.2.1  Pediatric Sales Threshold. Pediatric Sales of Product in the
                    Territory to the Pediatric Market do not exceed [**] during
                    calendar year 2000;

            12.2.2  Approved Indication. On or before [**], Sepracor has not
                    received Pediatric Bronchospasm Expanded Approval,
                    provided, however, that in such event Abbott shall only
                    have the right to terminate under this Section 12.2.2 by
                    giving written notice thereof to Sepracor on or before
                    [**] or

            12.2.3  Price Threshold. The average for any two consecutive
                    calendar quarters of the actual Average Net Selling
                    Price/Dose Vial of the Product is less than [**]; or

            12.2.4  One Year's Notice. At any time after December 31, 2000, upon
                    one year's prior written notice without cause.

                                       29
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

      12.3  Early Termination by Either Party. This Agreement may be terminated
            by either Party upon written notice to the other Party prior to the
            expiration of the Term or the Extension Term as follows:

            12.3.1  Material Breach. Ninety (90) days after notice from one
                    Party to the other Party that the receiving Party has
                    committed a material breach of this Agreement and at the end
                    of such ninety (90)-day period the receiving Party has not
                    cured or has not diligently, continuously, and in good faith
                    attempted to cure the described breach, with clear evidence
                    that such breach shall be cured within a period of an
                    additional sixty (60) days following the initial ninety
                    (90)-day period; provided, however, that the period for sure
                    shall be tolled during the pendency of an ADR initiated
                    pursuant to Article 19 to resolve whether such material
                    breach occurred; further provided, however, that Sepracor
                    shall not be in material breach for late payment if the
                    reason for late payment is lack of timely availability to
                    Sepracor of audit or survey data needed to make calculations
                    of Commissions.

            12.3.2  Force Majeure. Either Party giving ninety (90) days' prior
                    notice to the other Party if an event of Force Majeure as
                    described in Article 18 continues for more than six (6)
                    months. Termination pursuant to the application of this
                    Section shall not be deemed termination due to a material
                    breach of this Agreement by either Party.

            12.3.3  Bankruptcy. Either Party giving notice to the other Party in
                    the case of any adjudication of bankruptcy or insolvency,
                    appointment of a receiver by a court of competent
                    jurisdiction, assignment for the benefit of creditors, or
                    institution of liquidation proceedings by or against the
                    other Party. Termination pursuant to the application of this
                    Section shall not be deemed termination due to a material
                    breach of this Agreement by either Party.

            12.3.4  Price Established by Law. If any national or federal
                    legislation or regulation in the Territory shall establish a
                    maximum price which can be charged for the Product, which
                    price is less than [**] of the immediately preceding month's
                    average selling price per unit of Product, either Party may
                    give the other Party notice of termination at least ninety
                    (90) days prior to the effective date of termination.

            12.3.5  Conviction. If either Party, or one of its corporate
                    officers who is involved in the activities and business
                    arrangements set forth in this Agreement, shall be convicted
                    in any court of a violation of law, or found liable in a
                    civil action, from which no appeal can be taken, under
                    circumstances that materially negatively affect the rate of
                    reimbursement and eligibility for reimbursement with state
                    and government agencies that provide reimbursement for the
                    use of the

                                       30
<PAGE>

CONFIDENTIAL

                    Product by Purchasers, then ninety (90) days after notice
                    from the other Party this Agreement shall terminate.

            12.3.6  Merger/Acquisition. In the event a Third Party acquires
                    control of a Party, or all or substantially all of the
                    assets or stock of a Party is acquired by a Third Party,
                    through purchase, merger, consolidation or otherwise
                    (collectively referred to herein as an "Acquisition Event"),
                    the acquired Party will send the other Party written notice
                    of the Acquisition Event, and by no later than thirty (30)
                    days following the other Party's receipt of such notice, if
                    in the reasonable business judgment of the other Party such
                    Acquisition Event would have an adverse impact on the
                    co-promotion arrangement established by this Agreement, the
                    other Party may terminate this Agreement upon thirty (30)
                    days written notice to the acquired Party.

      12.4  Grace Period. The Parties hereby agree that from the Effective Date
            through March 31, 2000 (the "Grace Period"), while each Party will
            use reasonable commercial efforts to satisfy its obligations under
            this Agreement, a Party's failure to completely satisfy its
            obligations under Section 3.1.1, Section 3.1.2, Section 3.6, Section
            4.10.1, Section 4.10.2, or Section 4.15, as appropriate, during the
            Grace Period shall not constitute a material breach of the
            Agreement.

Article 13. CONSEQUENCES OF TERMINATION.

      13.1  Confidential Information. In the event of expiration or termination
            of this Agreement for any reason, both Parties shall cease using all
            Confidential Information, as defined in Section 15.1, supplied by
            the other Party. Upon either Party's request, the other shall return
            to its owner all written and/or tangible Confidential Information,
            except for one archive copy that may be retained by the legal
            department of a Party solely for the purpose of determining any
            continuing obligations. Both Parties and their Affiliates shall
            continue to be bound by the provisions of Article 15 for a period of
            five (5) years after the expiration or termination of this Agreement
            or ten (10) years after the execution of this Agreement, whichever
            is later.

      13.2  Accrued Obligations. Termination of this Agreement shall not relieve
            the Parties of any liability which accrued prior to the effective
            date of such termination, nor prejudice either Party's right to
            obtain performance of any obligation provided for in this Agreement
            which expressly survives termination.

      13.3  Return of Promotional Materials. Upon termination or expiration of
            this Agreement: (a) Abbott shall, at Sepracor's election and
            expense, either destroy or return to Sepracor all Sepracor
            Promotional Materials relating to the Product then in Abbott's
            possession; and (b) Sepracor shall, at Abbott's election and
            expense, either destroy or return to Abbott all Abbott Product
            Materials then in Sepracor's possession.

                                       31
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

      13.4  Commission. If this Agreement is terminated prior to the expiration
            of the Term or any Extension Term, then the applicable Commission
            for the Product for the Sales Year in which such termination
            occurred shall be the product of (a) the Pediatric Sales during such
            Sales Year, and (b) a blended Commission rate determined by
            annualizing the Pediatric Sales during such Sales Year.

      13.5  Residual Commission. The Parties acknowledge and agree that in the
            Territory, through the Abbott Promotional Efforts, Abbott will
            enhance the Product and the goodwill associated with the Product,
            Trademarks and other property of Sepracor. Therefore, upon
            expiration of this Agreement or early termination of this Agreement
            (a) by Abbott [**] or (b) by Sepracor [**] or (c) by or on behalf of
            Sepracor [**], Sepracor shall pay to Abbott the Residual Commission
            for a period of [**] immediately following any such early
            termination or expiration of the Term in an amount equal to:

            13.5.1  For the [**] period after such termination or expiration of
                    the Term, the Residual Commission shall be equal to [**] of
                    the Pediatric Sales during such 12-month period;

            13.5.2  For the [**] period after such termination or expiration of
                    the Term, the Residual Commission paid shall be an amount
                    equal to [**] of the Pediatric Sales during such 12-month
                    period; and

            13.5.3  For the [**] period after such termination or expiration of
                    the Term, the Residual Commission paid shall be an amount
                    equal to [**] of the Pediatric Sales during such 12-month
                    period.

            Sepracor shall pay the Residual Commission in quarterly installments
            due within fifteen (15) days after Sepracor's receipt, after the
            last day each applicable quarter, of all data from external sources
            necessary to calculate the Residual Commission during the three (3)
            periods of twelve (12) months.

      13.6  Remedies. Excepting any award granted pursuant to Article 19,
            neither Party shall be liable to the other Party for any
            compensation, reimbursement, damages for loss of prospective profits
            on anticipated revenue, or on account of expenses incurred,
            investments made, leases, commitments, or any other obligations
            incurred in connection with this Agreement as a result of any
            termination of this Agreement according to the terms of this
            Agreement or by reason of non-renewal of the Term. In any event,
            neither Party shall be liable to the other Party for any exemplary,
            indirect, incidental, or consequential damages.

      13.7  Survival. Upon termination of this Agreement or expiration of the
            Term, each Party shall provide to the other Party the reports and
            information necessary to calculate the Commission and any Residual
            Commission and compensation to Sepracor Representatives and Abbott
            Representatives. Without limitation, the

                                       32
<PAGE>

CONFIDENTIAL

            following Articles or Sections shall survive termination of this
            Agreement or expiration of the Term for a period of five (5) years
            (unless otherwise stated in such Article or Section): Article 1
            (Definitions), Article 10 (Representations and Warranties and
            Covenants), Article 13, Article 14, Article15, Article17, Article19
            and Sections 20.1, 20.4 and 20.7.

Article 14. INDEMNIFICATION.

      14.1  Sepracor Indemnification. Except as may be otherwise provided
            herein, Sepracor shall defend, indemnify and hold Abbott, its
            Affiliates, their successors and assigns, and all of their officers,
            directors, employees and representatives harmless from and against
            all suits, claims, liabilities, costs, damages, judgments and other
            expenses (including, but not limited to, reasonable legal expenses)
            suffered or incurred in connection with:

            14.1.1  Sepracor's breach of any of the Sepracor representations,
                    warranties, covenants or other terms or conditions of this
                    Agreement;

            14.1.2  A claim arising from the promotion of the Product or use of
                    the Trademark or Sepracor Marks in Sepracor Promotional
                    Materials or Abbott Product Materials;

            14.1.3  Any patent infringement claim arising from the manufacture,
                    marketing, promotion, importation, sale or use of the
                    Product;

            14.1.4  Any claim (including, but not limited to claims made with
                    respect to Sepracor advertising, Sepracor training of Abbott
                    Representatives or Sepracor Promotional Materials) made by a
                    Third Party against Abbott, its Affiliates, their successors
                    or assigns, or their officers, directors, employees or
                    representatives relating to the Product or the manufacture,
                    marketing, promotion, importation, sale or use of the
                    Product, including, but not limited to, death or personal
                    injury; or

            14.1.5  The negligence, recklessness or willful misconduct on the
                    part of Sepracor, its officers, directors, employees, agents
                    (except to the extent Abbott may be deemed an agent of
                    Sepracor by operation of law) or representatives with
                    respect to the Product or Samples, or in the performance of
                    the Agreement;

            provided, however, that Sepracor shall not be required to defend,
            indemnify or hold harmless Abbott, its Affiliates, their successors
            and assigns, or their officers, directors, employees or
            representatives with respect to any claim arising out of or
            resulting from (a) the negligence, recklessness, or willful
            misconduct of Abbott, its Affiliates, their successors and assigns,
            or their officers, directors, employees or representatives in the
            performance of their obligations hereunder, or (b) any breach by
            Abbott of this Agreement. For purposes of this Section, Abbott shall
            not be considered negligent if such claim arises in connection with
            Abbott's performance under this Agreement, so long

                                       33
<PAGE>

CONFIDENTIAL

            as such performance was in accordance with the terms of this
            Agreement; nor shall Abbott be considered negligent for purposes of
            this Section, if (a) such claim arises with respect to content of
            Sepracor's advertising, Sepracor Promotional Materials, Product
            labeling or other materials provided to Abbott by Sepracor as long
            as such Sepracor Promotional Materials are used in their original
            form and Abbott has distributed or employed such Sepracor
            Promotional Materials or other such materials as directed herein, or
            (b) such claim arises with respect to the Abbott Promotion Efforts
            by Abbott Representatives performed in accordance with direction,
            goals, or strategy for promoting Product described in this
            Agreement.

      14.2  Abbott Indemnification. Except as may be otherwise provided herein,
            Abbott shall defend, indemnify and hold Sepracor, its Affiliates,
            their successors and assigns, and all of their officers, directors,
            employees and representatives harmless from and against all suits,
            claims, liabilities, costs, damages, judgments and other expenses
            (including, but not limited to, reasonable legal expenses) suffered
            or incurred in connection with:

            14.2.1  Abbott's breach of any Abbott representations, warranties,
                    covenants or terms or conditions of this Agreement;

            14.2.2  A claim arising from Sepracor's use of the Abbott Marks in
                    Sepracor Promotional Materials or Abbott Product Materials;

            14.2.3  Any claim arising out of or in connection with Abbott's
                    promotion of Product not in accordance with direction,
                    goals, or strategy for promoting Product pursuant to this
                    Agreement; or

            14.2.4  The negligence, recklessness or willful misconduct on the
                    part of Abbott, its officers, directors, Abbott
                    Representatives, and other Abbott employees, agents, or
                    representatives with respect to the Product or Samples, or
                    in the performance under this Agreement;

            provided, however, that Abbott shall not be required to defend,
            indemnify, or hold harmless Sepracor, its Affiliates, their
            successors and assigns, or their officers, directors, employees or
            representatives with respect to any claim arising out of or
            resulting from (a) the negligence, recklessness, or willful
            misconduct of Sepracor, its Affiliates, their successors and
            assigns, or their officers, directors, employees or representatives
            in the performance of their obligations hereunder or (b) any breach
            by Sepracor of this Agreement. For purposes of this Section, Abbott
            shall not be considered negligent if such claim arises in connection
            with Abbott's performance under this Agreement so long as such
            performance was in accordance with the terms of this Agreement; nor
            shall Abbott be considered negligent for purposes of this Section,
            if (a) such claim arises with respect to the content of Sepracor's
            advertising, the Sepracor Promotional Materials, Product labeling or
            other materials provided to Abbott by Sepracor as long as such
            Sepracor Promotional Materials are used in their

                                       34
<PAGE>

CONFIDENTIAL

            original form and Abbott has distributed or employed such Sepracor
            Promotional Materials or such other materials as directed herein, or
            (b) such claim arises with respect to Abbott Promotional Efforts by
            Abbott Representatives performed in accordance with direction and
            teachings of the training described in this Agreement.

      14.3  Sepracor Indemnification Under Sampling Act. Without limiting any
            other provision herein:

            14.3.1  Sepracor shall perform under this Agreement in strict
                    accordance with the provisions of the Sampling Act.

            14.3.2  Sepracor shall defend, indemnify and hold Abbott and
                    Abbott's officers, directors, employees and sales
                    representatives harmless from and against all suits, claims,
                    liabilities, costs, damages, penalties, judgments and other
                    expenses (including, but not limited to, reasonable legal
                    expenses) arising out of or resulting from any violations of
                    the Sampling Act that are caused by Sepracor, its officers,
                    its directors, Sepracor representatives, and other
                    employees, agents, or representatives of Sepracor in
                    performance hereunder.

            14.3.3  If the conviction of a Sepracor representative under any
                    provision referred to in 21 U.S.C. ss.333(b)(2) occurs and
                    is deemed a Sepracor Diversion Violation for which Sepracor
                    is required to indemnify Abbott as set forth in Section
                    14.3.2, then:

                    14.3.3.1  If a Sepracor Diversion Violation is the first
                              Abbott violation of the provisions referred to in
                              21 U.S.C.ss.333(b)(2), then Sepracor shall
                              indemnify Abbott for any civil penalties incurred
                              by Abbott under 21 U.S.C.ss.333(b)(2)(A) on
                              account of such Sepracor Diversion Violation.
                              However, if, within a 10-year period following
                              such Sepracor Diversion Violation, Abbott receives
                              a third conviction for violating a provision
                              referred to in 21 U.S.C. ss.333(b)(2), Sepracor
                              shall indemnify Abbott for civil penalties
                              incurred by Abbott under 21 U.S.C.ss.333(b)(2)(B)
                              on account of such third conviction, less any
                              civil penalties incurred by Abbott under 21
                              U.S.C.ss.333(b)(2)(A) for which Sepracor has
                              indemnified Abbott hereunder.

                    14.3.3.2  If a Sepracor Diversion Violation is the second or
                              third conviction of Abbott for violating the
                              provisions referred to in 21 U.S.C. ss.333(b)(2)
                              in any 10-year period, then Sepracor shall
                              indemnify Abbott for any civil penalties incurred
                              by Abbott pursuant to 21 U.S.C.ss.333(b)(2)(A) or
                              (B), as applicable, on account of such Sepracor
                              Diversion Violation and, in addition, shall pay
                              Abbott as

                                       35
<PAGE>

CONFIDENTIAL

                              liquidated damages all reasonable legal,
                              accounting, and other costs Abbott incurred in
                              defending any Sepracor Diversion Violation. Such
                              liquidated damages, together with Sepracor's
                              payment of all civil penalties incurred by Abbott,
                              shall be Abbott's sole and exclusive remedy under
                              this Section 14.3.3.2 notwithstanding any other
                              provisions of this Agreement.

                    14.3.3.3  Except pursuant to Section 14.3.2 above or in the
                              event of Sepracor Diversion Violations, Sepracor
                              shall not have any obligation or liability of any
                              kind to Abbott in the event of a fourth or
                              subsequent violation of the provisions referred to
                              in 21 U.S.C.ss.333(b)(2) within a ten (10) year
                              period, regardless of whether one (1) or more of
                              the first three (3) convictions against Abbott was
                              an Sepracor Diversion Violation.

      14.4  Abbott Indemnification Under Sampling Act. Without limiting any
            other provision herein:

            14.4.1  Abbott shall perform under this Agreement in strict
                    accordance with the provisions of the Sampling Act.

            14.4.2  Abbott shall defend, indemnify and hold Sepracor and
                    Sepracor's officers, directors, employees and sales
                    representatives harmless from and against all suits, claims,
                    liabilities, costs, damages, penalties, judgments and other
                    expenses (including, but not limited to, reasonable legal
                    expenses) arising out of or resulting from any violations of
                    the Sampling Act that are caused by Abbott, its officers,
                    its directors, Abbott Representatives, and other employees,
                    agents, or representatives of Abbott in performance
                    hereunder.

            14.4.3  If the conviction of an Abbott representative under any
                    provision referred to in 21 U.S.C. ss.333(b)(2) occurs and
                    is deemed an Abbott Diversion Violation for which Abbott is
                    required to indemnify Sepracor as set forth in Section
                    14.4.2, then:

                    14.4.3.1  If an Abbott Diversion Violation is the first
                              Sepracor violation of the provisions referred to
                              in 21 U.S.C.ss.333(b)(2), then Abbott shall
                              indemnify Sepracor for any civil penalties
                              incurred by Sepracor under 21
                              U.S.C.ss.333(b)(2)(A) on account of such Abbott
                              Diversion Violation. However, if, within a 10-year
                              period following such Abbott Diversion Violation,
                              Sepracor receives a third conviction for violating
                              a provision referred to in 21 U.S.C.ss.333(b)(2),
                              Abbott shall indemnify Sepracor for

                                       36
<PAGE>

CONFIDENTIAL

                              civil penalties incurred by Sepracor under 21
                              U.S.C.ss.333(b)(2)(B) on account of such third
                              conviction, less any civil penalties incurred by
                              Sepracor under 21 U.S.C.ss.333(b)(2)(A) for which
                              Abbott has indemnified Sepracor hereunder.

                    14.4.3.2  If an Abbott Diversion Violation is the second or
                              third conviction of Sepracor for violating the
                              provisions referred to in 21 U.S.C.ss.333(b)(2) in
                              any 10-year period, then Abbott shall indemnify
                              Sepracor for any civil penalties incurred by
                              Sepracor pursuant to 21 U.S.C.ss.333(b)(2)(A) or
                              (B), as applicable, on account of such Abbott
                              Diversion Violation and, in addition, shall pay
                              Sepracor as liquidated damages all reasonable
                              legal, accounting, and other costs Sepracor
                              incurred in defending any Abbott Diversion
                              Violation. Such liquidated damages, together with
                              Abbott's payment of all civil penalties incurred
                              by Sepracor, shall be Sepracor's sole and
                              exclusive remedy under this Section 14.4.3.2
                              notwithstanding any other provisions of this
                              Agreement.

                    14.4.3.3  Except pursuant to Section 14.4.2 above or in the
                              event of Abbott Diversion Violations, Abbott shall
                              not have any obligation or liability of any kind
                              to Sepracor in the event of a fourth or subsequent
                              violation of the provisions referred to in 21
                              U.S.C.ss.333(b)(2) within a ten (10) year period,
                              regardless of whether one (1) or more of the first
                              three (3) convictions against Sepracor was an
                              Abbott Diversion Violation.

      14.5  Control of Defense. Each party agrees to promptly give the other
            party notice of any claim for which indemnification might be sought.
            Failure of an indemnified party to provide notice of a claim to the
            indemnifying party shall affect the indemnified party's right to
            indemnification only to the extent that such failure has a material
            adverse effect on the indemnifying party's ability to defend or the
            nature or the amount of the indemnified claim, liability, costs,
            damages, penalties, judgments and other expenses (referred to in
            this Section as "Liability"). The indemnifying party shall have the
            right to assume the defense and settlement of any suit or claim
            related to the Liability if it has assumed responsibility for the
            suit or claim in writing; provided, however, if in the reasonable
            judgment of the indemnified party, such suit or claim involves an
            issue or matter which could have an adverse impact on the assets of
            the indemnified party, or such suit or claim could require the
            indemnified party to engage in any activities that would have an
            adverse effect on the business operations or good will of the
            indemnified party, the indemnified party may waive its rights to
            indemnity under this Agreement and control the defense or settlement
            thereof, but in no event shall any such waiver be construed as a

                                       37
<PAGE>

CONFIDENTIAL

            waiver of any indemnification rights such party may have at law or
            in equity. If the indemnifying party defends the suit or claim, the
            indemnified party may participate in (but not control) the defense
            thereof at its sole cost and expense.

      14.6  Settlement of Claims. Neither party may settle or compromise a claim
            or action related to an indemnified matter without the written
            consent of the other party, if such settlement would impose any
            monetary obligation on the other party or require the other party to
            submit to an injunction or otherwise limit the other party's rights
            under this Agreement; provided that such consent shall not
            unreasonably be withheld or delayed, unless such settlement would
            have an adverse impact on the assets of the indemnified party, or
            such settlement would require the indemnified party to engage in any
            activities that would have an adverse effect on the business
            operations or good will of the indemnified party.

Article 15. CONFIDENTIALITY.

      15.1  Definition. Subject to Section 15.2, "Confidential Information"
            shall mean any and all notebooks, documents, memoranda, reports,
            files, books, correspondence, customer and other lists, other
            written, graphic and computer-stored records, information, data, and
            the like, whether in written, graphic, or verbal form, stored now or
            hereafter existing during the Term, together with all subsequent
            changes and additions of one Party (the "Owner") which was received
            directly by the other Party (the "Holder") or the Holder's agents,
            officers, or employees, which the Holder shall use, construct,
            observe, possess, or control, which affect or relate to the Product
            or the business of the Owner solely with regard to the Product,
            including but not limited to all information relating to: (a)
            marketing, sales, investigations, clinical trials, patient data,
            related materials, NDA, IND, copyrights, trademarks, all
            applications, submissions, modifications, supplements, permits,
            approvals, authorizations, licenses, customer lists, and records, to
            the extent all such items listed in this Section are not a matter of
            public record; (b) improvements to and inventions made to improve
            the Product, whether or not patentable, which Owner, Holder, or
            others makes, conceives, learns and/or reduces to practice, either
            alone or jointly with each other or with others, directly relating
            to the Product; and (c) financial, marketing, sales, billing,
            collection, Third Party payment procedures and issues, and customer
            data relating to the Product or Owner.

      15.2  Exceptions to the Definition of Confidential Information.
            Notwithstanding the provisions in Section 15.1, the term
            "Confidential Information" shall not include the following:

            15.2.1  Information which is now in the public domain or
                    subsequently enters the public domain without disclosure or
                    delivery thereof to the public on the part of the Holder in
                    breach of this Agreement;

                                       38
<PAGE>

CONFIDENTIAL

            15.2.2  Information which the Holder receives in good faith from a
                    Third Party and the Holder has no knowledge of such Third
                    Party obtaining the information by wrongful means;

            15.2.3  Information which has been independently developed by or for
                    the Holder without reference to the Confidential Information
                    of the Owner;

            15.2.4  Information which has been lawfully received by the Holder
                    without an obligation of confidentiality from a source other
                    than the Owner; and

            15.2.5  Information which is required to be disclosed by law,
                    government order or judicial order, but only to the extent
                    of disclosure to such authorities.

      15.3  Confidentiality Obligations. Holder shall use Confidential
            Information of the Owner solely for the purposes of this Agreement.
            Holder will disclose Confidential Information to Holder's and its
            Affiliates' employees, contractors and agents only on a need-to-know
            basis. Except for the uses permitted pursuant to the terms of this
            Agreement, Holder shall not disclose, make use of, or make available
            to any person any portion of the Confidential Information without
            Owner's prior written consent. Holder shall take all reasonable
            steps to ensure that the Confidential Information of Owner is held
            in confidence by Holder, its Affiliates and their employees,
            contractors and agents, except for the use permitted pursuant to the
            terms and conditions of this Agreement. Upon the termination or
            expiration of this Agreement the restrictions against disclosing any
            Confidential Information without Owner's prior written consent shall
            continue for the period set forth in Section 13.1.

      15.4  Previous Agreement. As of the Effective Date, this Agreement shall
            supersede the Confidentiality Agreement effective July 1, 1999,
            between the Parties as it relates to the Product. Any information
            received by either Party with respect to the Product shall hereafter
            be governed by the terms and conditions of this Agreement.

Article 16. PUBLIC ANNOUNCEMENTS.

      16.1  Joint Announcement. Each Party agrees that prior to any joint
            announcement of the Parties with respect to this Agreement, except
            as may be required by law, it shall not disclose the substance or
            details of this Agreement without the prior written consent of the
            other Party; provided, however, nothing contained herein shall be
            deemed to prohibit Sepracor from issuing any publicity, press
            release or announcement relating to the Product which does not
            mention Abbott or refer to this Agreement. In cases in which
            disclosure may be required by law, the disclosing Party, prior to
            such disclosure, shall notify the non-disclosing Party of the
            contents of the proposed disclosure. Consistent with applicable law,
            the

                                       39
<PAGE>

CONFIDENTIAL

            non-disclosing Party shall have the right to make reasonable changes
            to the disclosure to protect its interests. The disclosing Party
            shall not unreasonably refuse to include such changes in its
            disclosure. Once a joint announcement has been made, neither Party
            shall have any obligation of non-disclosure with respect to, but
            only to the extent of, information thereby announced.

      16.2  Non-Publicity.

            16.2.1  The Parties agree that the terms and conditions of this
                    Agreement are Confidential Information and, unless otherwise
                    specifically permitted hereby, may not be the subject of any
                    public announcement or press release by either, unless
                    permitted by Section 16.1. The Parties agree that upon
                    execution of this Agreement, a press release approved by
                    both Parties will be issued. Neither Party may:

            16.2.2  Issue or originate any publicity, public announcement, or
                    news release (written or oral) whether to the public press
                    or otherwise; or

                    16.2.2.1  Use the name of the other Party in any publicity,
                              public announcement, or news release regarding the
                              Agreement without the prior approval of the other
                              Party.

            16.2.3  There shall be a fourteen (14) day period of review of any
                    publicity or press release proposed by either Party,
                    allowing the other Party the opportunity to request and make
                    changes and to determine approval of such publicity or press
                    release. This document shall not be filed in any public
                    office or records without the written approval of the other
                    Party, including the right of redaction of language to
                    protect the reviewing Party's confidential and strategic
                    information and right to review language in any public
                    filings.

Article 17. TRADEMARKS.

      17.1  Promotion. Abbott shall promote the Product in the Territory only
            under the Trademark or other such marks as the Parties mutually
            agree in writing and using trade names, service marks and devices
            approved by Sepracor and only using Sepracor Promotional Materials
            or Abbott Product Materials approved by Sepracor pursuant to Section
            5.6.

      17.2  Compliance with Laws. Abbott shall, when referring to Sepracor Marks
            and the Trademark and labels, trade names, trade dress, service
            marks or devices, comply with all laws pertaining to trademarks,
            service marks, trade dress or other intellectual property rights at
            any time in force in the Territory.

      17.3  No Assertion of Right. Abbott shall not have, assert or acquire any
            right, title or interest in or to the Sepracor Marks, the Trademark
            or any part of any label, trade name, trade dress, service mark or
            device applied by Sepracor.

                                       40
<PAGE>

CONFIDENTIAL

Article 18. FORCE MAJEURE. Failure of either party to perform its obligations
under this Agreement (except the failure to make any payment when due) shall not
subject such party to any liability to the other if such failure is caused or
occasioned by act of god, or the public enemy, fire, explosion, flood, drought,
war, riot, sabotage, embargo, strikes, or other labor trouble, failure in whole
or in part, of Sepracor's suppliers to deliver on schedule materials, equipment
or machinery to Sepracor, interruption of or delay in transportation, compliance
with any order, regulation or request of any government of competent
jurisdiction or any officer, department, agency or committee thereof, including
requisition or allocation or establishment of priority, or by compliance with a
request authorized by such governmental authority of any manufacturer for
material to be used by it, which event is beyond the reasonable control of the
Party so failing. The Party suffering an event of force majeure shall
immediately notify the other party and shall use all reasonable efforts to
minimize the damages suffered by both parties. Both Parties shall cooperate in
good faith in order to minimize such damages and, subject to the provisions of
Article 19, reach an agreement as to how to proceed.

Article 19. ALTERNATIVE DISPUTE RESOLUTION. Any controversy or claim arising out
of or relating to this agreement, or the breach thereof, shall first be
submitted to the president of the Ross Products Division of Abbott (or designee)
and the president (or designee) of Sepracor for resolution. If resolution of the
matter is not reached by such individuals, then such dispute shall be resolved
through the alternative dispute resolution described in Schedule 9; provided,
however, each party shall have the right during or before any ADR to seek and
obtain from an appropriate court, remedies to avoid irreparable harm, maintain
the status quo, or preserve the subject matter of the ADR.

Article 20. GENERAL.

      20.1  Property Interest. Sepracor shall retain all property interests in
            the Product until the point of sale, and in all Samples and Sepracor
            Promotional Materials until their distribution by Abbott, or its
            representatives or agents. Sepracor shall not assign or transfer any
            right or interest in relation to the Product in any manner which
            could affect Abbott's ability to exploit its rights under this
            Agreement.

      20.2  Assignment. Neither Party may assign or transfer any right or
            interest under this Agreement without the prior written consent of
            the other Party; provided, however, that in the event a Party merges
            with a Third Party or sells all or substantially all of its business
            unit to which this Agreement relates, that Party may assign this
            Agreement to any successor by merger or sale of all or substantially
            all of its business unit to which the Agreement relates without the
            consent of the other Party; further, provided, however, that in the
            event Sepracor sells all or substantially all of its business to
            which this Agreement relates to a Third Party in a transaction in
            which this Agreement is not transferred to such Third Party by
            operation of law, then as part of such transaction the Third Party
            shall assume this agreement from Sepracor either (a) with the
            condition that it remain in effect for one (1) year following
            Sepracor's written notice to Abbott regarding such transaction (the
            "Transfer Period"), and upon termination of the Transfer Period, the
            Agreement will terminate and the Residual Commission set

                                       41
<PAGE>

CONFIDENTIAL

            forth in Section 13.5 shall apply; or (b) without the condition set
            forth in (a) above.

      20.3  Headings. All headings and titles are for reference purposes only
            and shall not in any way affect the meaning or interpretation of
            this Agreement.

      20.4  Notices.

            20.4.1  Methods: All notices or other communications required or
                    permitted to be given shall be in writing, shall be signed
                    by an authorized officer of the relevant Party, and given to
                    the recipient Party by hand delivery; pre-paid mail sent to
                    that Party, or by facsimile, to the address, as set forth
                    below, with written proof of receipt. All notices, consents,
                    approvals, orders, acceptances and requests shall be in
                    writing addressed to the Parties at the following addresses,
                    respectively.

            20.4.2  Addresses:

                    If to Sepracor:           President
                                              Sepracor Inc.
                                              111 Locke Drive, Suite 2
                                              Marlborough, Massachusetts 01752
                                              Facsimile: 508-357-7492

                    If to Abbott:             President
                                              Ross Products Division
                                              Abbott Laboratories
                                              625 Cleveland Avenue
                                              Columbus, Ohio 43215
                                              Facsimile: 614-624-7030

                    With a copy to:           Senior Division Counsel
                                              Domestic Legal Operations
                                              Abbott Laboratories
                                              625 Cleveland Avenue
                                              Columbus, Ohio 43215
                                              Facsimile: 614-624-3704

            20.4.3  Change of Address. A Party may change its address set forth
                    above by giving a notice in writing, at least five (5)
                    business days prior to the effective date, to all other
                    Parties, stating the new address and the effective date of
                    the change.

            20.4.4  Deemed Date of Receipt. Documents sent by prepaid mail shall
                    be deemed to have been received by the addressee on the
                    second business day after posting. Facsimile messages shall
                    be deemed to have been received by the addressee on the date
                    of transmission, provided that if the transmission is not on
                    a business day or not before 4:00 p.m. at the

                                       42
<PAGE>

CONFIDENTIAL

                    location of the recipient's address set forth in Section
                    20.4.2, then it shall be deemed to have been received by the
                    addressee on the next succeeding business day after
                    transmission.

      20.5  Waiver. No failure on the part of either Party to exercise, and no
            delay in exercising, any right or remedy shall operate as a waiver
            of such right or remedy, nor shall any single or partial exercise of
            any right or remedy preclude any further or other exercise of such
            right or remedy. All rights and remedies under this Agreement are
            cumulative and shall not be deemed exclusive of any other rights or
            remedies provided by law except as otherwise provided herein.

      20.6  Severability. If any Section or portion(s) thereof contained in this
            Agreement is declared invalid by any court of competent jurisdiction
            or a government agency having jurisdiction, the remainder of this
            Agreement, and the application of such provision to persons or
            circumstances other than those to which it is held invalid by such
            court, shall not be affected thereby, and the Agreement shall remain
            in full force and effect. To the extent possible, the Parties shall
            reform such invalidated Section or portion(s) thereof in a manner
            that will render such provision valid without impairing the Parties'
            original intent.

      20.7  Governing Law. The laws of the State of Delaware shall govern the
            interpretation, performance and enforcement of this Agreement,
            without respect to the conflict of laws provisions.

      20.8  Counterparts. This Agreement may be executed in counterparts, each
            of which shall be deemed to be an original and all of which, when
            taken together, shall constitute the Agreement.

      20.9  Entire Agreement. This Agreement contains the entire understanding
            between the Parties hereto with respect to the subject matter
            hereof. This Agreement cannot be amended, except by a writing signed
            by all Parties.

      IN WITNESS WHEREOF, each of the Parties has by its duly authorized
representative signed and entered into this Agreement as of the day and year
first above written.

ABBOTT LABORATORIES INC.                 SEPRACOR INC.

By: /s/ Joy Amundson                        By: /s/ William James O'Shea
   --------------------------------------   ---------------------------
   Joy Amundson                             William James O'Shea
   President, Ross Products Division        President & Chief Operating Officer

                                       43
<PAGE>

CONFIDENTIAL

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                                  SCHEDULE 1.32

                       Sample Pediatric Sales Calculation
                        (For Illustration Purposes Only)

[**]

                                       1
<PAGE>

CONFIDENTIAL

                                 SCHEDULE 10.4.6

                       Other Agreements Regarding Product

      Sales Force Services Agreement between Innovex Inc. and Sepracor Inc.,
effective August 1, 1999.

                                       1
<PAGE>

CONFIDENTIAL

                                 SCHEDULE 10.4.7

                              Notices From The FDA

1)    Untitled letter from the FDA's Division of Drug Marketing, Advertising and
      Communications ("DDMAC") dated March 26, 1999.

2)    Untitled letter from DDMAC dated May 21, 1999.

                                       1
<PAGE>

CONFIDENTIAL

                                   SCHEDULE 19

                         ALTERNATIVE DISPUTE RESOLUTION

      The Parties recognize that a bona fide dispute as to certain matters may
arise from time to time during the Term which relates to either Party's rights
and/or obligations under the Agreement. To have such a dispute resolved by ADR,
a Party first must send written notice of the dispute to the other Party for
attempted resolution by good faith negotiations between their respective
representatives identified in Article 19 of the Agreement within twenty-eight
(28) calendar days ("Days") after such notice is received (hereinafter "Initial
Period").

      If the matter has not been resolved during the Initial Period, or if the
Parties fail to meet within such Initial Period, either Party may initiate an
ADR proceeding as set forth Paragraphs 1.1 to 1.10 below. Each Party, at its
sole cost and expense, shall have the right to be represented by counsel in such
a proceeding.

      1.1   To begin an ADR proceeding, a Party shall provide written notice to
            the other Party of the issues to be resolved by ADR (the "ADR
            Notice") within fourteen (14) Days of expiration of the Initial
            Period. Within fourteen (14) Days after its receipt of such ADR
            Notice, the other Party may, by written notice to the Party
            initiating the ADR, add additional issues to be resolved within the
            same ADR.

      1.2   Within twenty-one (21) Days following receipt of the original ADR
            Notice (the "Selection Period"), the Parties shall select a mutually
            acceptable neutral individual ("Neutral Party") to preside in the
            resolution of any disputes in this ADR proceeding. If the Parties
            are unable to agree on a mutually acceptable Neutral Party within
            the Selection Period, the Parties shall request the President of the
            Center for Public Resources ("CPR"), 366 Madison Avenue, New York,
            New York 10017, to select a Neutral Party pursuant to the following
            procedures:

            1.2.1 The CPR shall submit to the Parties a list of not less than
                  five (5) candidates within fourteen (14) Days after receipt of
                  the request from the Parties, along with a curriculum vitae
                  for each candidate. No candidate shall be an employee,
                  director, or shareholder of either Party or any of the
                  subsidiaries or Affiliates of any Party.

            1.2.2 Such list shall include a statement of disclosure by each
                  candidate of any circumstances likely to affect his or her
                  impartiality.

            1.2.3 Each Party shall number the candidates in order of preference
                  (with the number one (1) signifying the greatest preference)
                  and shall deliver the list to the CPR within seven (7) Days
                  following receipt of the list of candidates. If a Party
                  believes a conflict of interest exists regarding any of the
                  candidates, that Party shall provide a written explanation of
                  the conflict to the CPR along with its list showing its order
                  of preference for the candidates. Any Party failing to return
                  a list of preferences on time shall be deemed to have no order
                  of preference.

                                       1
<PAGE>

CONFIDENTIAL

            1.2.4 If the Parties collectively have identified fewer than three
                  (3) candidates deemed to have conflicts, the CPR immediately
                  shall designate the Neutral Party as the candidate for whom
                  the Parties collectively have indicated the greatest
                  preference. If a tie should result between two candidates, the
                  CPR, in its sole discretion, may designate either candidate.
                  If the Parties collectively have identified three (3) or more
                  candidates deemed to have conflicts, the CPR shall review the
                  explanations regarding conflicts and, in its sole discretion,
                  may either:

                  1.2.4.1 Immediately designate as the Neutral Party the
                          candidate for whom the Parties collectively have
                          indicated the greatest preference, or

                  1.2.4.2 Issue a new list of not less than five (5) candidates,
                          in which case the procedures set forth in
                          Subparagraphs 1.2.1 to 1.2.4 above shall be repeated.

1.3         No earlier than twenty-eight (28) Days and no later than fifty-six
            (56) Days after selection of the Neutral Party, the Neutral Party
            shall hold a hearing to resolve each of the issues identified by the
            Parties. The ADR hearing shall take place at a location agreed upon
            by the Parties. If the Parties cannot agree, the Neutral Party shall
            designate a location other than the principal place of business of
            either Party or any of their subsidiaries or Affiliates.

1.4         At least seven (7) Days prior to the ADR hearing, each Party shall
            submit the following to the other Party and the Neutral Party:

            1.4.1 A copy of all exhibits on which such Party intends to rely in
                  any oral or written presentation to the Neutral Party;

            1.4.2 A list of any witnesses such Party intends to call at the ADR
                  hearing, and a short summary of the anticipated testimony of
                  each witness;

            1.4.3 A proposed ruling on each issue to be resolved, together with
                  a request for a specific damage award or other remedy for each
                  issue. The proposed rulings and remedies shall not contain any
                  recitation of the facts or any legal arguments and shall not
                  exceed one (1) page per issue.

            1.4.4 A brief in support of such Party's proposed rulings and
                  remedies, provided that the brief shall not exceed twenty (20)
                  pages. This page limitation shall apply regardless of the
                  number of issues raised in the ADR.

            1.4.5 Except as expressly set forth in Subparagraphs 1.4.1 through
                  1.4.4 above, no discovery shall be required or permitted by
                  any means, including depositions, interrogatories, requests
                  for admissions, or production of documents.

                                       2
<PAGE>

CONFIDENTIAL

1.5   The ADR hearing shall be conducted on two (2) consecutive Days and shall
      be governed by the following rules:

      1.5.1 Each Party shall be entitled to five (5) hours of hearing time to
            present its case. The Neutral Party shall be the sole and absolute
            judge of whether each Party has had the five (5) hours to which it
            is entitled.

      1.5.2 Each Party shall be entitled, but not required, to make an opening
            statement, to present regular and rebuttal testimony, documents or
            other evidence, to cross-examine witnesses, and to make a closing
            argument. Cross-examination of witnesses shall occur immediately
            after their direct testimony, and cross-examination time shall be
            charged against the Party conducting the cross-examination.

      1.5.3 The Party initiating the ADR shall begin the hearing and, if it
            chooses to make an opening statement, shall address not only issues
            it has raised but also any issues raised by the responding Party.
            The responding Party, if it chooses to make an opening statement,
            also may address all issues raised in the ADR. Thereafter, the
            presentation of regular and rebuttal testimony and documents, other
            evidence, and closing arguments shall proceed in the same sequence.

      1.5.4 Except for their own direct testimony, witnesses shall be excluded
            from all hearings until closing arguments.

      1.5.5 Neither affidavits nor settlement negotiations shall be admissible
            under any circumstances. As to all other matters, the Neutral Party
            shall have sole discretion regarding the admissibility of any
            evidence.

1.6   Within seven (7) Days following completion of the ADR hearing, each Party
      may submit to the other Party and the Neutral Party a post-hearing brief
      in support of its proposed rulings and remedies, provided that such brief
      shall not contain or discuss any evidence not introduced during the
      hearings and shall not exceed ten (10) pages. This page limitation shall
      apply regardless of the number of issues raised in the ADR proceeding.

1.7   The Neutral Party shall rule on each disputed issue within fourteen (14)
      Days following completion of the ADR hearing. Such ruling may adopt in its
      entirety the proposed ruling and remedy of one of the Parties on each
      disputed issue, or may adopt one Party's proposed rulings and remedies on
      some issues and the other Party's proposed rulings and remedies on other
      issues. The Neutral Party shall not issue any written opinion or otherwise
      explain the basis of the ruling.

1.8   The Neutral Party shall be paid a reasonable fee plus expenses. The
      Neutral Party's fees and expenses , along with the fees and expenses of a
      court reporter, and any expenses for a hearing room, shall be split and
      paid fifty/fifty (50/50) by the Parties. All other costs and expenses
      associated with the ADR shall be borne solely and exclusively by the Party
      incurring such costs and expenses.

                                       3
<PAGE>

CONFIDENTIAL

1.9   The rulings of the Neutral Party shall be binding, non-reviewable, and
      non-appealable, and may be entered as a final judgment in any court having
      jurisdiction.

1.10  Except as provided in Paragraph 1.9 above or as required by law, the
      existence of the dispute, any settlement negotiations, the ADR hearing,
      any submissions (including exhibits, testimony, proposed rulings, and
      briefs), and the rulings shall be deemed Confidential Information. The
      Neutral Party shall have the authority to impose sanctions for
      unauthorized disclosure of Confidential Information.

                                       4<PAGE>

                                                            Exhibit 10.35

                                 SUMMARY OF PLAN
        REGARDING "PARACHUTE PAYMENTS" AND SECTION 280G GROSS-UP PAYMENTS

     1.   NATURE OF PLAN. The plan is not an employment contract or
employment contracts and does not specify any terms or conditions of
employment. The Plan provides for certain benefits to officers or employees
of Sepracor Inc. in the event of a "Change in Ownership or Control" of
Sepracor (as further defined below).

     2.    TERM. The Plan takes effect upon approval of the Board of
Directors and expires on December 31, 2004; provided that (i) it is subject
to automatic one-year extensions unless notice of prior to termination of the
original plan or any extension is given by Sepracor, and (ii) each officer or
employee is entitled to the benefits provided therein if a Change in
Ownership or Control occurs during the term of the Plan.

     3.    BENEFITS: TAX TREATMENT

           a.   TAX TREATMENT. The Internal Revenue Code imposes certain tax
penalties on both Sepracor and the officer or employee if the amount of
severance payments to the officer of employee following a Change in Ownership
or Control exceeds certain limits (generally three times the average of the
employee's compensation over the previous five years).

     If a Contingent Compensation Payment (as defined below) is made or is
made available to an officer or employee, then Sepracor or its successors
agree to make a Gross-Up Payment (as defined below) to the officer or
employee.

           b.   NO MITIGATION. The benefits payable to the officer or
employee are not reduced by payments received by the officer or employee from
a subsequent employer.

           c.   For purposes of this Section 3, the following terms shall
have the following respective meanings:

"Change in Ownership or Control" shall mean a change in the ownership or
effective control of the Company or in the ownership of a substantial portion
of the assets of the Company determined in accordance with Section 280G(b)(2)
of the Code.

"Contingent Compensation Payment" shall mean any payment (or benefit) in the
nature of compensation that is made or made available (under any agreement or
plan) to a "disqualified individual" (as defined in Section 280G(c) of the
Code) and that is contingent (within the meaning of Section 280G(b)(2)(A)(i)
of the Code) on a Change in Ownership or Control of the Company.

"Gross-Up Payment" shall mean an amount equal to the sum of (i) the amount of
the excise tax payable with respect to a Contingent Compensation Payment and
(ii) the amount necessary to pay all additional taxes imposed on (or
economically borne by) the officer or employee (including the excise taxes,
state and federal income taxes and all applicable withholding taxes)
attributable to the receipt of such Gross-Up Payment. For purposes of the
preceding sentence, all taxes attributable to the receipt of the Gross-Up
Payment shall be computed assuming the application of the maximum tax rates
provided by law.

     4.    SUCCESSOR TO COMPANY. The Company shall require any successor
(whether direct or indirect, by purchase, merger, consolidation or otherwise)
to all or substantially all of the business or assets of the Company
expressly to assume and agree to perform the Plan to the same extent that the
Company would be required to perform it if no such succession had taken
place. As used in the Plan, "Company" shall mean the Company as defined above
and any successor to its business or assets as aforesaid which assumes and
agrees to perform this Agreement, by operation of law or otherwise.

     5.    EXPENSES. Sepracor must pay, as incurred, all expenses which the
employee reasonably incurs as a result of any dispute relating to the Plan
(regardless of the outcome of such dispute).

     6.    AGREEMENTS. Sepracor may enter into agreements with one or more
officers or employees to reflect the provisions of the Plan but the Plan is
binding on Sepracor and its successors on and as of the date of approval or
the Board of Directors and whether or not Sepracor enters into agreements
with its officers or employees.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]